

09-29-00

Box See / A

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	G0307/7017 (JRV)
	First Named Inventor or Application Identifier	
	Stocker et al.	
	Express Mail Label No.	EL711220885US
	Date of Deposit	September 28, 2000

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i>	ADDRESS Box Patent Application TO: Commissioner for Patents Washington, DC 20231
1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i> 2. <input checked="" type="checkbox"/> Specification [Total pages 57] 50 - pages description 1 - pages abstract 6 - pages claims 46 - Total claims 3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total sheets] <input type="checkbox"/> Informal <input type="checkbox"/> Formal [Total drawings] 4. <input type="checkbox"/> Oath or Declaration [Total pages] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> [Note Box 5 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 5. <input type="checkbox"/> Incorporation by Reference <i>(usable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	6. <input type="checkbox"/> Microfiche Computer Program (Appendix) 7. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above ACCOMPANYING APPLICATION PARTS 8. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s) 9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney 10. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i> 11. <input type="checkbox"/> Information Disclosure Statement PTO-1449 <input type="checkbox"/> Copies of IDS Citations 12. <input type="checkbox"/> Preliminary Amendment 13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>
16. Other:	
17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: <input type="checkbox"/> Cancel in this application original claims of the prior application before calculating the filing fee. <input type="checkbox"/> Amend the specification by inserting before the first line the sentence: This application is a <input type="checkbox"/> continuation <input type="checkbox"/> divisional of application serial no. , filed , entitled , and now .	

18. CORRESPONDENCE ADDRESS					
Correspondence address below					
ATTORNEY'S NAME	John R. Van Amsterdam, Reg. No. 40,212				
NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	<i>John R. Van Amsterdam</i>
DATE	SEPTEMBER 28, 2000

P-GLYCOPROTEINS AND USES THEREOF

Related Applications

This application claims priority under 35 U.S.C. §119 from U.S. provisional patent
5 application 60/156,510, filed September 28, 1999.

Field of the Invention

The invention pertains to P-glycoproteins of dog (*Canis familiaris*).

Background of the Invention

10 P-glycoprotein (PGP; also known as multidrug transporter, MDR1) is a member of the ABC transporter superfamily and is expressed in the human intestine, liver and other tissues. This enzyme serves as an efflux pump exporting small molecules across the cell membrane. It has been known for several years that high level expression of PGP is a mechanism for
15 tumor resistance to cancer chemotherapy. Intestinal expression of PGP may affect the oral bioavailability of drug molecules that are substrates for this transporter. PGP can efficiently efflux drugs back into the intestinal lumen and thus reduce the amount of drug that enters into circulation.

20 The measurement of interaction with PGP can provide a better understanding of the reasons why particular drugs demonstrate low or high bioavailability. Interaction with PGP can be studied using either direct assays of drug transport in polarized cell systems or with indirect assays such as drug-stimulated ATPase activity and inhibition of the transport of fluorescent substrates.

25 Therefore there is a need for additional PGP polypeptides, preferably which are closely related to the human PGP, for use in the foregoing drug assays.

Summary of the Invention

30 Nucleic acids encoding P-glycoprotein of dog (*Canis familiaris*) have now been identified, isolated, cloned and sequenced. This PGP is closely related (has a high degree of identity) to the human PGP. The invention provides isolated nucleic acid molecules, unique fragments of those molecules, expression vectors containing the foregoing, and host cells transfected with those molecules. The invention also provides isolated polypeptides and

inhibitors of the foregoing nucleic acids and polypeptides which reduce drug transport. The PGP nucleic acids and polypeptides are useful in assays for evaluating bioavailability of drugs, as well as for the optimization or discovery of drugs. In addition, the foregoing can be used in the diagnosis or treatment of conditions characterized by PGP activity and can be used in methods in which it is therapeutically useful to increase or decrease PGP activity.

According to one aspect of the invention, an isolated nucleic acid molecule is provided which is selected from the group consisting of (a) nucleic acid molecules that code for the amino acid sequence of SEQ ID NO:2, (b) allelic variants of (a), wherein the allelic variants exclude SEQ ID NO:3 and SEQ ID NO:5, and (c) complements of (a) or (b).

Preferred allelic variants include nucleic acid molecules that encode an amino acid sequence selected from the group consisting of SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27, particularly nucleotide sequences selected from the group consisting of SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26. In preferred embodiments the isolated nucleic acid molecule codes for SEQ ID NO:2, or comprises the nucleotide sequence of SEQ ID NO:1. In particularly preferred embodiments, the nucleic acid molecules comprise or consist of the coding region of the aforementioned nucleotide sequences.

According to other aspects of the invention, isolated P-glycoprotein polypeptides or fragments thereof are provided. The polypeptides include at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 25, 192, 197, 212, 288, 329, 532, 696, 1273 and 1355 of SEQ ID NO:2; amino acid 25 of SEQ ID NO:23; and amino acids 25 and 1148 of SEQ ID NO:25. Other isolated P-glycoprotein polypeptides or fragments thereof include at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 3, 6, 8, 10, 12, 14-26, 36, 38, 48, 52, 56, 64, 74, 78, 84-92, 94, 96, 98, 99, 101, 103, 104, 106, 108, 112, 115, 147, 187, 197, 199, 233, 288, 321, 326, 347, 397, 450, 454, 455, 467, 472, 520, 633, 637, 643, 644, 650, 657, 658, 661, 666, 667, 674-677, 679, 685, 689, 691, 693, 694, 703, 707, 717, 731, 736, 740, 744, 745, 756, 759, 763, 853, 914, 920, 942, 943, 946, 968-970, 972, 974, 983, 1005, 1010, 1017, 1025, 1026, 1029, 1040, 1095, 1098, 1105, 1144, 1148, 1149, 1158, 1162, 1165, 1168, 1170, 1252 and 1279 of SEQ ID NO:2; and amino acid 329 of SEQ ID NO:27, wherein the P-glycoprotein is identical to a human P-glycoprotein except for the at least one amino acid of a dog P-glycoprotein. In certain embodiments, the human P-glycoprotein is selected from the group of SEQ ID NO:7 and SEQ ID NO:8. Still other isolated P-glycoprotein polypeptides or fragments thereof

include at least one amino acid of a dog P-glycoprotein that is different from a cynomologous P-glycoprotein, wherein the P-glycoprotein is identical to a cynomologous monkey P-glycoprotein except for the at least one amino acid of a dog P-glycoprotein. Yet other polypeptides include combinations of the foregoing dog, human and cynomologous PGP polypeptides. In preferred embodiments, the isolated P-glycoprotein polypeptides or fragments thereof include an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, fragments of SEQ ID NO:2, fragments of SEQ ID NO:23, fragments of SEQ ID NO:25 and fragments of SEQ ID NO:27.

According to still other embodiments of the invention, isolated nucleic acid molecules are provide which encode the foregoing isolated P-glycoprotein polypeptides or fragments thereof. Also included expression vectors comprising the foregoing isolated nucleic acid molecules operably linked to a promoter, as well as host cells transformed or transfected with the expression vectors.

In another aspect of the invention, agents which selectively binds the isolated PGP polypeptides are provided. Preferably the agent does not bind a human or dog P-glycoprotein, except those provided herein. In certain embodiments, the agent is a polypeptide preferably one selected from the group consisting of monoclonal antibodies, polyclonal antibodies, Fab antibody fragments, F(ab)₂ antibody fragments and antibody fragments including a CDR3 region. Also provided are agents which selectively binds the foregoing isolated nucleic acid molecules, preferably antisense nucleic acid molecules which selectively binds to the isolated nucleic acid molecule.

According to another aspect of the invention, methods for predicting the bioavailability of a compound are provided. The methods include measuring the transmembrane transport of a test compound by a first P-glycoprotein, comparing the transmembrane transport of the test compound by the first P-glycoprotein and a second P-glycoprotein to predict the bioavailability of the test compound, wherein the relative amount or rate of transport by the first P-glycoprotein and the second P-glycoprotein is predictive of bioavailability of the test compound. In certain embodiments the first P-glycoprotein is selected from the group consisting of dog P-glycoproteins and primate P-glycoproteins, preferably one of the foregoing polypeptides. In other embodiments the second P-glycoprotein is a human P-glycoprotein.

In still other aspects of the invention, methods for inhibiting P-glycoprotein

transporter activity in a mammalian cell are provided. The methods include contacting the mammalian cell with an amount of one of the foregoing agents effective to inhibit P-glycoprotein transporter activity in the mammalian cell.

Also included in the invention are methods for increasing bioavailability of a drug in a subject. The methods include administering to a subject in need of such treatment one of the foregoing agents in an amount effective to increasing bioavailability of a drug. The inhibitor can be administered prior to administering the drug, or concurrently with the drug.

Also provided are methods for increasing P-glycoprotein transporter activity in a cell. These methods include contacting the cell with a molecule selected from the group consisting of the foregoing nucleic acid molecules, in an amount effective to increase P-glycoprotein transporter activity in the cell. The cell can be contacted under conditions whereby the P-glycoprotein is expressed.

According to yet another aspect of the invention, methods for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with P-glycoprotein transporter activity are provided. The methods include providing a cell or other membrane-encapsulated space comprising a P-glycoprotein as provided herein; contacting the cell or other membrane-encapsulated space with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of P-glycoprotein transporter activity; and determining a second amount of P-glycoprotein transporter activity as a measure of the effect of the pharmacological agent on the P-glycoprotein transporter activity, wherein a second amount of P-glycoprotein transporter activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces P-glycoprotein transporter activity and wherein a second amount of P-glycoprotein transporter activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases P-glycoprotein transporter activity. The methods can further include a step of loading the cell or other membrane-encapsulated space with a detectable compound, wherein the compound is detected as a measure of the P-glycoprotein transporter activity.

Also included are methods for identifying compounds which selectively bind a P-glycoprotein. The methods include contacting a P-glycoprotein provided herein with a compound, and determining the binding of the compound to the P-glycoprotein. The methods

can further include determining the effect of the compound on the P-glycoprotein transporter activity of the P-glycoprotein or determining the effect of the compound on the ATPase activity of the P-glycoprotein.

Additional methods provided according to the invention include methods for
5 determining ATPase activity of a P-glycoprotein. The methods include contacting a host cell as provided above, or a membrane fraction thereof, with a test drug, and measuring ATPase activity of the P-glycoprotein. In certain embodiments, the step of measuring ATPase activity is performed at least twice at different times. Also provided methods for determining transmembrane transport of a compound by a P-glycoprotein. The methods include
10 contacting a host cell provided above, or a membrane fraction thereof, with a test drug, and measuring transport of the test drug under sink conditions in at least one direction of transport selected from the group consisting of the apical to basolateral direction and the basolateral to apical direction. In certain embodiments the step of measuring transport of the test drug is performed at least twice at different times.

15 These and other aspects of the invention are described in greater detail below.

Brief Description of the Sequences

SEQ ID NO:1 is the nucleotide sequence encoding dog P-glycoprotein (Genotype C).

SEQ ID NO:2 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID
20 NO:1.

SEQ ID NO:3 is the nucleotide sequence encoding a prior art dog P-glycoprotein (GenBank accession number AF045016).

SEQ ID NO:4 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID
NO:3.

25 SEQ ID NO:5 is the nucleotide sequence encoding another prior art dog P-glycoprotein (GenBank accession number AF092810).

SEQ ID NO:6 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID
NO:5.

30 SEQ ID NO:7 is the amino acid sequence of a prior art human P-glycoprotein, having Genbank accession number M14758.

SEQ ID NO:8 is the amino acid sequence of a second prior art human P-glycoprotein, having Genbank accession numbers AF016535 or NM_000927.

SEQ ID NO:9 is the nucleotide sequence of a PCR primer homologous to human
PGP1.

SEQ ID NO:10 is the nucleotide sequence of a PCR primer homologous to dog PGP2.

SEQ ID NO:11 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

5 SEQ ID NO:12 is the nucleotide sequence of a PCR primer homologous to human
PGP1.

SEQ ID NO:13 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:14 is the nucleotide sequence of a PCR primer homologous to human

PGP1.

10 SEQ ID NO:15 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:16 is the nucleotide sequence of a PCR primer homologous to human

PGP1.

SEQ ID NO:17 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:18 is the nucleotide sequence of a PCR primer homologous to vector.

15 SEQ ID NO:19 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:20 is the nucleotide sequence of a PCR primer homologous to human

PGP1.

SEQ ID NO:21 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:22 is the nucleotide sequence encoding dog P-glycoprotein (Genotype A).

20 SEQ ID NO:23 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ
ID NO:22.

SEQ ID NO:24 is the nucleotide sequence encoding dog P-glycoprotein (Genotype B).

SEQ ID NO:25 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ

ID NO:24.

25 SEQ ID NO:26 is the nucleotide sequence encoding dog P-glycoprotein (Genotype D).

SEQ ID NO:27 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ

ID NO:25.

SEQ ID NO:28 is the nucleotide sequence of the cDNA synthesis primer from the
Marathon cDNA Amplification Kit.

30 SEQ ID NO:29 is the nucleotide sequence of the cDNA Adapter Primer 1 from the
Marathon cDNA Amplification Kit.

SEQ ID NO:30 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:31 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:32 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

Detailed Description of the Invention

5 The present invention in one aspect involves the identification of novel cDNAs encoding dog P-glycoproteins, referred to herein as dog PGP. The nucleotide sequence of a dog PGP (termed "Genotype C") is presented as SEQ ID NO:1, and the amino acid sequence of this dog PGP is presented as SEQ ID NO:2.

10 Three allelic variants of Genotype C dog PGP were isolated ("Genotype A", "Genotype B" and "Genotype D"). The nucleotide and amino acid sequences of Genotype A are presented as SEQ ID NOs:20 and 21, respectively. The amino acid sequence of Genotype A differs from the amino acid sequence of Genotype C at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2. The nucleotide and amino acid sequences of Genotype B are presented as SEQ ID NOs:22 and 23, respectively.

15 The amino acid sequence of Genotype B differs from the amino acid sequence of Genotype C at amino acid 25 (asparagine → lysine) based on a T → A change at nucleotide 91 of SEQ ID NO:2, and at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2. The nucleotide and amino acid sequences of Genotype D are presented as SEQ ID NOs:24 and 25, respectively. The amino acid sequence of Genotype D differs
20 from the amino acid sequence of Genotype C at amino acid 25 (asparagine → lysine) based on a T → A change at nucleotide 91 of SEQ ID NO:2, at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2, at amino acid 329 (serine → threonine) based on a T → A change at nucleotide 1001 of SEQ ID NO:2, and at amino acid 1148 (methionine → valine) based on a A → G change at nucleotide 3458 of SEQ
25 ID NO:2.

30 Two closely related dog PGP sequence were deposited in GenBank under accession numbers AF045016 (complete cDNA) and AF092810 (partial cDNA). Whereas much of the polypeptides presented herein is identical to the known dog PGPs, the dog PGPs of the invention (SEQ ID NOs:2, 21, 23 and 25) have several single amino acid differences from the prior art sequences, including at least one deletion. These allelic differences in the very highly conserved protein domains of the P-glycoprotein are entirely unexpected.

 The invention involves in one aspect dog PGP nucleic acids and polypeptides, as well

as therapeutics relating thereto. The invention also embraces isolated functionally equivalent variants, useful analogs and fragments of the foregoing nucleic acids and polypeptides; complements of the foregoing nucleic acids; and molecules which selectively bind the foregoing nucleic acids and polypeptides.

5 The dog PGP nucleic acids and polypeptides of the invention are isolated. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA
10 techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or
15 expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

 As used herein with respect to polypeptides, "isolated" means separated from its
20 native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term
25 "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in
30 that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

 As used herein a dog PGP nucleic acid refers to an isolated nucleic acid molecule

which codes for a dog PGP polypeptide. Such nucleic acid molecules code for dog PGP polypeptides which include the amino acid sequences of SEQ ID NO:2, 23, 25, 27 and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:1, and nucleotide sequences which differ from the sequences of SEQ ID NO:1, in codon
5 sequence due to the degeneracy of the genetic code. The dog PGP nucleic acids of the invention also include alleles (e.g., SEQ ID Nos: 22, 24, 26) of the foregoing nucleic acids (except those of previously known dog PGP alleles, e.g., SEQ ID NOS:3 and 5), and encoded polypeptides, as well as fragments of the foregoing nucleic acids and polypeptides. Such fragments can be used, for example, as probes in hybridization assays and as primers in a
10 polymerase chain reaction (PCR). Preferred dog PGP nucleic acids include the nucleic acid sequences of SEQ ID NOS:1, 22, 24, 26 and fragments thereof. Complements of the foregoing nucleic acids also are embraced by the invention.

As used herein "dog PGP activity" refers to an ability of a PGP polypeptide to export small molecules across the cell membrane. A molecule which inhibits dog PGP activity (an
15 antagonist) is one which inhibits export of small molecules via PGP and a molecule which increases dog PGP activity (an agonist) is one which increases export of small molecules via PGP. Changes in dog PGP activity can be measured by assays such as those disclosed herein, including efflux of fluorescent compounds from cells.

Alleles of the dog PGP nucleic acids of the invention can be identified by conventional
20 techniques. For example, alleles of dog PGP can be isolated by hybridizing a probe which includes at least a fragment of SEQ ID NO:1 under stringent conditions with a cDNA library and selecting positive clones. Thus, an aspect of the invention is those nucleic acid sequences which code for dog PGP polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:1 under stringent conditions (except those of previously known dog
25 PGP alleles, e.g., SEQ ID NOS:3 and 5). The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel,
30 et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM

NaH₂PO₄(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C.

5 There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of alleles of dog PGP nucleic acids of the invention. The skilled artisan also is familiar with the
10 methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

 In screening for dog PGP nucleic acids, a Southern blot may be performed using the foregoing stringent conditions, together with a radioactive probe. After washing the
15 membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal.

 The dog PGP nucleic acids of the invention also include degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six
20 codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating dog PGP polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and
25 CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of
30 the genetic code.

 The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these

modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as transporter activity, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated fragments of SEQ ID NO:1. The fragments can be used as probes in Southern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. Smaller fragments are those comprising 12, 13, 14, 15, 16, 17, 18, 20, 22, 25, 30, 40, 50, or 75 nucleotides, and every integer therebetween, and are useful e.g. as primers for nucleic acid amplification procedures. As known to those skilled in the art, larger probes such as 200, 250, 300, 400 or more nucleotides are preferred for certain uses such as Southern blots, while smaller fragments will be preferred

for uses such as PCR. Fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments. Likewise, fragments can be employed to produce non-fused fragments of the dog PGP polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and the like. The foregoing nucleic acid fragments further can be used as antisense molecules to inhibit the expression of dog PGP nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

The invention also includes functionally equivalent variants of the dog PGP, which include variant nucleic acids and polypeptides which retain one or more of the functional properties of the dog PGP. For example, variants include a fusion protein which includes the extracellular and transmembrane domains of the dog PGP which retains the ability to transport molecules. Still other functionally equivalent variants include truncations, deletions, point mutations, or additions of amino acids to the sequence of SEQ ID NO:1 which retains functions of SEQ ID NOs:2, e.g., the alleles presented herein. Functionally equivalent variants also include a dog PGP which has had a portion of the N-terminus removed or replaced by a similar domain from another P-glycoprotein (e.g. a “domain-swapping” variant). Other functionally equivalent variants will be known to one of ordinary skill in the art, as will methods for preparing such variants. The activity of a functionally equivalent variant can be determined using the methods provided herein, and in references that have described assays using P-glycoproteins of other species. Such variants are useful, *inter alia*, for evaluating bioavailability of drugs, in assays for identification of compounds which bind and/or regulate the transporter function of the dog PGP, and for determining the portions of the dog PGP which are required for transporter activity.

Variants which are non-functional also can be prepared as described above. Such variants are useful, for example, as negative controls in experiments testing transporter activity.

A dog PGP nucleic acid, in one embodiment, is operably linked to a gene expression sequence which directs the expression of the dog PGP nucleic acid within a eukaryotic or prokaryotic cell. The “gene expression sequence” is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the dog PGP nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a

constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPTR), adenosine deaminase, pyruvate kinase, β -actin promoter and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of Moloney murine leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined dog PGP nucleic acid. The gene expression sequences optionally includes enhancer sequences or upstream activator sequences as desired.

The dog PGP nucleic acid sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the dog PGP coding sequence under the influence or control of the gene expression sequence. If it is desired that the dog PGP sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the dog PGP sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the dog PGP sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a dog PGP nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that dog PGP nucleic acid sequence such that the

resulting transcript might be translated into the desired protein or polypeptide.

The dog PGP nucleic acid molecules and the dog PGP polypeptides (including the dog PGP inhibitors described below) of the invention can be delivered to the eukaryotic or prokaryotic cell alone or in association with a vector. In its broadest sense, a “vector” is any vehicle capable of facilitating: (1) delivery of a dog PGP nucleic acid or polypeptide to a target cell, (2) uptake of a dog PGP nucleic acid or polypeptide by a target cell, or (3) expression of a dog PGP nucleic acid molecule or polypeptide in a target cell. Preferably, the vectors transport the dog PGP nucleic acid or polypeptide into the target cell with reduced degradation relative to the extent of degradation that would result in the absence of the vector.

Optionally, a “targeting ligand” can be attached to the vector to selectively deliver the vector to a cell which expresses on its surface the cognate receptor (e.g. a receptor, an antigen recognized by an antibody) for the targeting ligand. In this manner, the vector (containing a dog PGP nucleic acid or a dog PGP polypeptide) can be selectively delivered to a specific cell. In general, the vectors useful in the invention are divided into two classes: biological vectors and chemical/physical vectors. Biological vectors are more useful for delivery/uptake of dog PGP nucleic acids to/by a target cell. Chemical/physical vectors are more useful for delivery/uptake of dog PGP nucleic acids or dog PGP proteins to/by a target cell.

Biological vectors include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the nucleic acid sequences of the invention, and free nucleic acid fragments which can be linked to the nucleic acid sequences of the invention. Viral vectors are a preferred type of biological vector and include, but are not limited to, nucleic acid sequences from the following viruses: retroviruses, such as Moloney murine leukemia virus; Harvey murine sarcoma virus; murine mammary tumor virus; Rous sarcoma virus; adenovirus; adeno-associated virus; SV40-type viruses; polyoma viruses; poxviruses; retroviruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; and polio virus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but

incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "*Gene Transfer and Expression, A Laboratory Manual*," W.H. Freeman C.O., New York (1990) and Murry, E.J. Ed. "*Methods in Molecular Biology*," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication-deficient and is capable of infecting a wide range of cell types and species. It further has advantages, such as heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a dog PGP polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which

contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992).

In addition to the biological vectors, chemical/physical vectors may be used to deliver a dog PGP nucleic acid or polypeptide to a target cell and facilitate uptake thereby. As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the isolated dog PGP nucleic acid or polypeptide to a cell.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vesicles which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2 - 4.0 μ can encapsulate large macromolecules. RNA, DNA, and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, v. 6, p. 77 (1981)). In order for a liposome to be an efficient nucleic acid transfer vector, one or more of the following characteristics should be present: (1) encapsulation of the nucleic acid of interest at high efficiency with retention of biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information.

Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to a particular cell will depend on the particular cell or tissue type. Additionally when the vector encapsulates a nucleic acid, the vector may be coupled to a nuclear targeting peptide, which will direct the dog PGP nucleic acid to the nucleus of the host cell.

Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleoyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications.

Other exemplary compositions that can be used to facilitate uptake by a target cell of the dog PGP nucleic acids include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a dog PGP nucleic acid into a preselected location within a target cell chromosome).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the dog PGP cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include intestinal cells and liver cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also provides isolated dog PGP polypeptides which include the amino acid sequence of SEQ ID NO:2, and fragments thereof, encoded by the dog PGP nucleic acids described above. Dog PGP polypeptides also embrace alleles, such as SEQ ID NOS:23, 25 and 27 (except not SEQ ID NOS:3 and 5), functionally equivalent variants and analogs (those non-allelic polypeptides which vary in amino acid sequence from the disclosed dog PGP polypeptides by 1, 2, 3, 4, 5, or more amino acids) provided that such polypeptides retain dog PGP activity. Non-functional variants also are embraced by the invention; these are useful as antagonists of transporter function, as negative controls in assays, and the like. Such alleles, variants, analogs and fragments are useful, for example, alone or as fusion proteins for a variety of purposes including as a component of assays.

Fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the dog PGP polypeptide, in particular as a transporter of various molecules. Other functional capabilities which can be retained in a fragment of a dog PGP polypeptide include interaction with antibodies and interaction with other polypeptides (such as would be found in a protein complex). Those skilled in the art are well versed in methods for selecting fragments which retain a functional capability of the dog PGP. Confirmation of the functional capability of the fragment can be carried out by synthesis of the fragment and testing of the capability according to standard methods. For example, to test the transporter activity of a dog PGP fragment, one inserts or expresses the fragment in a cell in which molecular transport can be measured. Such methods, which are standard in the art, are described further herein.

The invention embraces variants of the dog PGP polypeptides described above. As used herein, a “variant” of a dog PGP polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a dog PGP polypeptide. Modifications which create a dog PGP variant can be made to a dog PGP polypeptide for a variety of reasons, including 1) to reduce or eliminate an activity of a dog PGP polypeptide, such as transport; 2) to enhance a property of a dog PGP polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a dog PGP polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to establish that an amino acid substitution does or does not affect molecular transport activity. Modifications to a dog PGP polypeptide are typically made to the nucleic acid which encodes the dog PGP polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the dog PGP amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus “design” a variant dog PGP according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary a only a portion of the polypeptide sequence. By applying the computational methods of

Dahiyat and Mayo, specific variants of a dog PGP polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

Variants include dog PGP polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a dog PGP polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a dog PGP polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with a desired property. Further mutations can be made to variants (or to non-variant dog PGP polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a dog PGP gene or cDNA clone to enhance expression of the polypeptide.

The activity of variants of dog PGP polypeptides can be tested by cloning the gene encoding the variant dog PGP polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant dog PGP polypeptide, and testing for a functional capability of the dog PGP polypeptides as disclosed herein. For example, the variant dog PGP polypeptide can be tested for ability to provide molecular transport (e.g., efflux), as set forth below in the examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in dog PGP polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e, variants which retain the functional capabilities of the dog PGP

polypeptides. As used herein, a “conservative amino acid substitution” refers to an amino acid substitution which does not alter the relative charge or size characteristics of the polypeptide in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the dog PGP polypeptides include conservative amino acid substitutions of SEQ ID NO:2 or SEQ ID NO:4. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Conservative amino-acid substitutions in the amino acid sequence of dog PGP polypeptide to produce functionally equivalent variants of dog PGP typically are made by alteration of the nucleic acid sequence encoding dog PGP polypeptides (e.g., SEQ ID NO:1). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a dog PGP polypeptide. The activity of functionally equivalent fragments of dog PGP polypeptides can be tested by cloning the gene encoding the altered dog PGP polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered dog PGP polypeptide, and testing for the ability of the dog PGP polypeptide to mediate transmembrane transport of compounds. Peptides which are chemically synthesized can be tested directly for function.

A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated dog PGP molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce

polypeptide. Those skilled in the art also can readily follow known methods for isolating dog PGP polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

5 The invention as described herein has a number of uses, some of which are described elsewhere herein. For example, the invention permits isolation of the dog PGP polypeptide molecules by e.g., expression of a recombinant nucleic acid to produce large quantities of polypeptide which may be isolated using standard protocols. As another example, the isolation of the dog PGP gene makes it possible for dog PGP to be used in methods for
10 assaying of molecular transport, such as drug bioavailability studies. These methods involve determining transport of a drug by a first species' PGP (e.g., dog) in comparison to transport of the drug by other species' PGP (e.g. human) as a method for determining or predicting the bioavailability of the drug. Thus the results of whole animal studies on the metabolism of a drug can be evaluated in view of the relative rates or amounts of P-glycoprotein transport of
15 the drug. For example, if a drug administered to a dog has good oral bioavailability and low transport by dog PGP, one can predict that the oral bioavailability of the drug in humans will be good if the transport by human PGP is also low. Conversely, if the transport of the drug by human PGP is high, then the bioavailability of the drug would be predicted to be low.

20 The invention also embraces agents which bind selectively to the dog PGP nucleic acid molecules or polypeptides as well as agents which bind to variants and fragments of the polypeptides and nucleic acids as described herein. The agents include polypeptides which bind to dog PGP, and antisense nucleic acids, both of which are described in greater detail below. The agents can inhibit or increase dog PGP activity (antagonists and agonists, respectively).

25 Some of the agents are inhibitors. A dog PGP inhibitor is an agent that inhibits dog PGP mediated transport of molecules across a cell membrane. Efflux assays can be performed to screen and/or determine whether a dog PGP inhibitor has the ability to inhibit dog PGP activity, and whether the inhibition is selective. An exemplary assay of efflux is described below in the Examples.

30 In one embodiment the dog PGP inhibitor is an antisense oligonucleotide that selectively binds to a dog PGP nucleic acid molecule, to reduce the expression of dog PGP (or other species' PGPs) in a cell. This is desirable in virtually any medical condition wherein a

reduction of PGP transporter activity is desirable, e.g., to increase retention of cytotoxic agents in a cell.

As used herein, the term “antisense oligonucleotide” or “antisense” describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1, or upon allelic (except SEQ ID NOS:3 and 5) or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which polypeptides are not expected to bind. Thus, the present invention also provides for antisense

oligonucleotides which are complementary to allelic (except SEQ ID NOS:3 and 5) or homologous cDNAs and genomic DNAs corresponding to a dog PGP nucleic acid containing SEQ ID NO:1.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding dog PGP polypeptides, together with pharmaceutically acceptable carriers.

Agents which bind dog PGP also include binding peptides and other molecules which bind to the dog PGP polypeptide and complexes containing the dog PGP polypeptide. When the binding molecules are inhibitors, the molecules bind to and inhibit the activity of dog PGP. To determine whether a dog PGP binding agent binds to dog PGP any known binding assay may be employed. For example, the binding agent may be immobilized on a surface and then contacted with a labeled dog PGP polypeptide. The amount of dog PGP which interacts with the dog PGP binding agent or the amount which does not bind to the dog PGP binding agent may then be quantitated to determine whether the dog PGP binding agent binds to dog PGP.

The dog PGP binding agents include molecules of numerous size and type that bind selectively or preferentially to dog PGP polypeptides, and complexes of both dog PGP polypeptides and their binding partners. These molecules may be derived from a variety of sources. For example, dog PGP binding agents can be provided by screening degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the dog PGP polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the dog PGP polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences.

DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the dog PGP polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the dog PGP polypeptides. Thus, the dog PGP polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding

partners of the dog PGP polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of dog PGP and for other purposes that will be apparent to those of ordinary skill in the art.

5 Therefore the invention generally provides efficient methods of identifying pharmacological agents or lead compounds for agents useful in the treatment of conditions associated with aberrant PGP activity and the compounds and agents so identified. Generally, the screening methods involve assaying for compounds which inhibit or enhance transport of molecules through dog PGP. Such methods are adaptable to automated, high throughput
10 screening of compounds. Examples of such methods are described in US patent 5,429,921.

A variety of assays for pharmacological agents are provided, including, labeled *in vitro* protein binding assays, efflux assays using detectable molecules, etc. For example, protein binding screens are used to rapidly examine the binding of candidate pharmacological agents to a dog PGP. The candidate pharmacological agents can be derived from, for
15 example, combinatorial peptide libraries. Convenient reagents for such assays are known in the art. An exemplary cell-based assay of efflux involves contacting a cell having a dog PGP with a candidate pharmacological agent under conditions whereby the efflux of a detectably labeled molecule can occur. Specific conditions are well known in the art and are described , for example, in Sharom et al., *Biochem. Pharmacol.* 58:571-586, 1999, and references cited
20 therein. A reduction in the efflux in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent reduces the efflux activity of dog PGP. An increase in the efflux in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent increases the efflux activity of dog PGP.

Dog PGP used in the methods of the invention can be added to an assay mixture as an
25 isolated polypeptide (where binding of a candidate pharmaceutical agent is to be measured) or as a cell or other membrane-encapsulated space which includes a dog PGP polypeptide. In the latter assay configuration, the cell or other membrane-encapsulated space can contain the dog PGP as a preloaded polypeptide or as a nucleic acid (e.g. a cell transfected with an expression vector containing a dog PGP). In the assays described herein, the dog PGP
30 polypeptide can be produced recombinantly, or isolated from biological extracts, but preferably is synthesized *in vitro*. Dog PGP polypeptides encompass chimeric proteins comprising a fusion of a dog PGP polypeptide with another polypeptide, e.g., a polypeptide

capable of providing or enhancing protein-protein binding, or enhancing stability of the dog PGP polypeptide under assay conditions. A polypeptide fused to a dog PGP polypeptide or fragment thereof may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

5 The assay mixture also comprises a candidate pharmacological agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes,
10 although typically they are organic compounds. Preferably, the candidate pharmacological agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and
15 more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the
20 like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids having non-natural bonds or subunits are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including
25 expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily modified through conventional chemical, physical, and biochemical means. Further,
30 known pharmacological agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

Therefore, a source of candidate agents are libraries of molecules based on known P-glycoprotein inhibitors, in which the structure of the inhibitor is changed at one or more positions of the molecule to contain more or fewer chemical moieties or different chemical moieties. The structural changes made to the molecules in creating the libraries of analog inhibitors can be directed, random, or a combination of both directed and random substitutions and/or additions. One of ordinary skill in the art in the preparation of combinatorial libraries can readily prepare such libraries based on existing P-glycoprotein inhibitors.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the dog PGP mediates the efflux of a control amount of a compound such as a drug. For determining the binding of a candidate pharmaceutical agent to a dog PGP, the mixture is incubated under conditions which permit binding. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 1 minute and 10 hours.

After incubation, the level of efflux or the level of specific binding between the dog PGP polypeptide and the candidate pharmaceutical agent is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximize

signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead,
5 particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid
10 substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as a transmembrane transport assay. The transport of a directly or indirectly detectable product, e.g., a fluorescent molecule such as calcein AM or rhodamine 123, is preferred. For cell free
15 binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc). or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to a dog PGP polypeptide or the candidate pharmacological agent.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly
20 detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

The dog PGP binding agent may also be an antibody or a functionally active antibody fragment. Antibodies are well known to those of ordinary skill in the science of immunology. As used herein, the term "antibody" means not only intact antibody molecules but also fragments of antibody molecules retaining dog PGP binding ability. Such fragments are also
30 well known in the art and are regularly employed both *in vitro* and *in vivo*. In particular, as used herein, the term "antibody" means not only intact immunoglobulin molecules but also the well-known active fragments $F(ab')_2$, and Fab. $F(ab')_2$, and Fab fragments which lack the

Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983)).

Monoclonal antibodies may be made by any of the methods known in the art utilizing dog PGP, or a fragment thereof, as an immunogen. Alternatively the antibody may be a polyclonal antibody specific for dog PGP which inhibits dog PGP activity. The preparation and use of polyclonal antibodies is also known to one of ordinary skill in the art.

Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) *The Experimental Foundations of Modern Immunology* Wiley & Sons, Inc., New York; Roitt, I. (1991) *Essential Immunology*, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

In general, intact antibodies are said to contain "Fc" and "Fab" regions. The Fc regions are involved in complement activation and are not involved in antigen binding. An

antibody from which the Fc' region has been enzymatically cleaved, or which has been produced without the Fc' region, designated an "F(ab')₂" fragment, retains both of the antigen binding sites of the intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an
5 "Fab'" fragment, retains one of the antigen binding sites of the intact antibody. Fab' fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain, denoted "Fd." The Fd fragments are the major determinants of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity). Isolated Fd fragments retain the ability to specifically
10 bind to antigen epitopes.

The sequences of the antigen-binding Fab' portion of the anti-dog PGP monoclonal antibodies identified as being useful according to the invention in the assays provided above, as well as the relevant FR and CDR regions, can be determined using amino acid sequencing methods that are routine in the art. It is well established that non-CDR regions of a
15 mammalian antibody may be replaced with corresponding regions of non-specific or hetero-specific antibodies while retaining the epitope specificity of the original antibody. This technique is useful for the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Techniques to humanize antibodies are particularly useful when non-
20 human animal (e.g., murine) antibodies which inhibit dog PGP activity are identified. These non-human animal antibodies can be humanized for use in the treatment of a human subject in the methods according to the invention. Examples of methods for humanizing a murine antibody are provided in U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205. Other antibodies, including fragments of intact antibodies with antigen-binding
25 ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')₂, and Fab fragments of an anti-dog PGP monoclonal antibody; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-dog PGP antibody have been replaced by homologous human or non-
30 human sequences; chimeric F(ab')₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-dog PGP antibody have been replaced by homologous human or non-human sequences; and chimeric Fab fragment antibodies in which

the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences.

According to the invention dog PGP inhibitors also include “dominant negative” polypeptides derived from SEQ ID NOs:2. A dominant negative polypeptide is an inactive
5 variant of a polypeptide, which, by interacting with the cellular machinery, displaces an active polypeptide from its interaction with the cellular machinery or competes with the active polypeptide, thereby reducing the effect of the active polypeptide. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand.

10 The end result of the expression of a dominant negative dog PGP polypeptide of the invention in a cell is a reduction in PGP activity such as molecular transport. One of ordinary skill in the art can assess the potential for a dominant negative variant of a dog PGP polypeptide, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of a dog
15 PGP polypeptide, one of ordinary skill in the art can modify the sequence of the dog PGP polypeptide by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in
20 dog PGP activity and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a dog PGP polypeptide will be apparent to one of ordinary skill in the art.

Each of the compositions of the invention is useful for a variety of therapeutic and non-therapeutic purposes. For example, the dog PGP nucleic acids of the invention are useful
25 as oligonucleotide probes. Such oligonucleotide probes can be used herein to identify genomic or cDNA library clones possessing an identical or substantially similar nucleic acid sequence. A suitable oligonucleotide or set of oligonucleotides, which is capable of hybridizing under stringent hybridization conditions to the desired sequence, a variant or fragment thereof, or an anti-sense complement of such an oligonucleotide or set of
30 oligonucleotides, can be synthesized by means well known in the art (see, for example, *Synthesis and Application of DNA and RNA*, S.A. Narang, ed., 1987, Academic Press, San Diego, CA) and employed as a probe to identify and isolate the desired sequence, variant or

fragment thereof by techniques known in the art. Techniques of nucleic acid hybridization and clone identification are disclosed by Sambrook, et al., *Molecular Cloning, A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Plainview, NY (1989). To facilitate the detection of a desired nucleic acid sequence, or variant or fragment thereof, whether for cloning purposes or for the mere detection of the presence of the sequence, the above-described probes may be labeled with a detectable group. Such a detectable group may be any material having a detectable physical or chemical property. Such materials have been well-developed in the field of nucleic acid hybridization and, in general, many labels useful in such methods can be applied to the present invention. Particularly useful are radioactive labels. Any radioactive label may be employed which provides for an adequate signal and has a sufficient half-life. If single stranded, the oligonucleotide may be radioactively labeled using kinase reactions. Alternatively, oligonucleotides are also useful as nucleic acid hybridization probes when labeled with a non-radioactive marker such as biotin, an enzyme or a fluorescent group. See, for example, Leary, J.J., et al., *Proc. Natl. Acad. Sci. (USA)* 80:4045 (1983); Renz, M. et al., *Nucl. Acids Res.* 12:3435 (1984); and Renz, M., *EMBO J.* 6:817 (1983).

Additionally, complements of the dog PGP nucleic acids can be useful as antisense oligonucleotides, e.g., by delivering the antisense oligonucleotide to an animal to induce a dog PGP "knockout" phenotype. The administration of antisense RNA probes to block gene expression is discussed in Lichtenstein, C., *Nature* 333:801-802 (1988).

Alternatively, the dog PGP nucleic acid of the invention can be used to prepare a non-human transgenic animal. A "transgenic animal" is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), Harlan Sprague Dawley (Indianapolis, IN), etc. Transgenic animals having a particular property associated with a particular disease can be used to study the affects of a variety of drugs and treatment methods on the disease, and thus serve as genetic models for the study of a number of human diseases. The invention, therefore, contemplates the use of dog PGP knockout and transgenic animals as models for the study of disorders involving transport of molecules across cell membranes. A variety of methods

known to one of ordinary skill in the art are available for the production of transgenic animals associated with this invention.

Inactivation or replacement of the endogenous PGP/MDR1 gene can be achieved by a homologous recombination system using embryonic stem cells. The resultant transgenic non-human mammals having a PGP^{-/-} knockout phenotype may be made transgenic for the dog PGP and used as a model for screening compounds as modulators (agonists or antagonists/inhibitors) of the dog PGP. In this manner, such therapeutic drugs can be identified.

Additionally, a normal or mutant version of dog PGP can be inserted into the germ line to produce transgenic animals which constitutively or inducibly express the normal or mutant form of dog PGP. These animals are useful in studies to define the role and function of dog PGP in cells.

The compositions of the invention are also useful for therapeutic purposes. Accordingly the invention encompasses a method for inhibiting dog PGP activity in a mammalian cell. The invention further provides methods for reducing or increasing dog PGP activity in a cell. In one embodiment, the method involves contacting the mammalian cell with an amount of a dog PGP nucleic acid or polypeptide effective to inhibit molecular transport out of the mammalian cell. Such methods are useful *in vitro* for the purpose of, for example, elucidating the mechanisms involved in drug resistance and reduced drug bioavailability.

The invention also encompasses a method for increasing PGP expression in a cell or subject. The amount of dog PGP can be increased in such cell or subject by contacting the cell with, or administering to the subject, a PGP nucleic acid or a PGP polypeptide of the invention to the subject in an amount effective to increase transmembrane transport in the cell or the subject. An increase in PGP activity can be measured by the assays described herein, e.g., assays of transmembrane transport.

The preparations of the invention are administered in effective amounts. An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, produces the desired response. Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the

knowledge and expertise of the health practitioner. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

Generally, doses of active compounds would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable and in one or several administrations per day. Lower doses will result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compound, although fewer doses typically will be given when compounds are prepared as slow release or sustained release medications.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptably compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

The dog PGP inhibitors or dog PGP nucleic acids and polypeptides useful according to the invention may be combined, optionally, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled

with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; and phosphoric acid in a salt.

5 The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular compound selected, the severity of the condition being treated and the dosage required for therapeutic efficacy. The methods of the invention,
10 generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, intradermal, or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intrathecal, intramuscular, or infusion. Intravenous or
15 intramuscular routes are not particularly suitable for long-term therapy and prophylaxis.

The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly
20 and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous
25 liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the dog PGP inhibitor or dog PGP nucleic acids and polypeptides, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and
30 suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be

employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier
5 formulation suitable for oral, subcutaneous, intravenous, intrathecal, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

Other delivery systems can include time-release, delayed release or sustained release delivery systems such as the biological/chemical vectors is discussed above. Such systems
10 can avoid repeated administrations of the active compound, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. Use of a long-term sustained release implant may be desirable. Long-term release, as used herein, means that the implant is constructed and arranged to delivery therapeutic levels of the active ingredient for at least 30 days, and
15 preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above. The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

Examples

Example 1: Isolation of dog P-glycoprotein

cDNA libraries were prepared using dog (*Canis familiaris*) mRNA according to
25 standard procedures. The libraries were screened for P-glycoprotein clones using a human P-glycoprotein DNA probe. Clones were isolated, purified and sequenced in accordance with standard procedures, as described below.

Liver and lung tissue was excised from Beagle dog tissue samples and flash frozen in liquid nitrogen.

30 A 890bp fragment of dog PGP1 was PCR'd out of a lambda gt11 vector cDNA library custom made by Stratagene. PCR was done using reagents from Clontech. Primers were custom designed, one specific for sequence homologous to human PGP1, the other

homologous to dog PGP2.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dp1216F	5'-gaa ctg tga ttg cgt ttg gag gac-3'	24mer	9	human PGP1
Dp2133R	5'-ttc agg gcc gcc tgt acc tct g-3'	22mer	10	dog PGP2

PCR was performed with a Perkin Elmer 9700 thermocycler. PCR was done at 94°C for 2 minutes, followed by 40 cycles of 94°C for 30 seconds, 40°C for 20 seconds and 72°C for 2 minutes and 30 seconds, and then incubated at 72°C for 3 minutes. The PCR product was run on a 1% agarose gel, and stained with EtBr. The DNA band at 917bp was cut out, and purified using the QIAquick Gel Extraction kit from Qiagen Inc.

The DNA was then ligated to the vector pCR2.1 using the Original TA Cloning kit from Invitrogen. INValphaF' cells were transformed with the ligation retain, a colony was selected, grown up in 100mL of L broth with ampicillin. DNA purification was done using the Plasmid Midi purification kit from Qiagen. The insert was sequenced using an ABI 377 sequencer. This sequence corresponds to an 890bp fragment of dog PGP, from base 816 to base 1706 in the open reading frame.

Five other fragments were isolated, cloned and sequenced using the same method as stated above, with any differences in procedure stated below.

RNA extraction from dog lung tissue was performed using Nucliobond RNA Maxi Prep. purification kit from Clontech. cDNA was synthesized from the RNA preparation using Superscript Preamplification System for First Strand cDNA Synthesis from Life Technologies.

Fragment 1: cDNA source-dog lung cDNA library prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm1766F	5'-ccc cac aga tgg cat ggt ctg t-3'	22mer	11	dog PGP1
Dp2769R	5'-cgc ttg gtg agg atc tct cca gc-3'	23mer	12	human PGP1

This corresponds to a 981bp fragment of dog PGP from base 1364 to base 2345 in the open reading frame.

Fragment 2: cDNA source dog - lung cDNA library prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm2037F	5'-aga aac aga gaa tcg cca ttg ctc-3'	24mer	13	dog PGP1

Dp3793R 5'-gct gca gtc aaa cag gat ggg ct-3' 23mer 14 human PGP1

This corresponds to a 1728bp fragment of dog PGP from base 1635 to base 3362 in the open reading frame.

5 Fragment 3: cDNA source dog - lung cDNA prep

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm3411F	5'-agt tca ttt gct cct gac tat gcc-3'	24mer	15	dog PGP1
Dp4214R	5'-gat gcc ttt ctg ggc cag cag c-3'	22mer	16	human PGP1

This corresponds to a 779bp fragment of dog PGP from base 3004 to base 3783 in the open reading frame.

An RNA preparation from dog liver tissue was performed using the same method as used previously. cDNA was made from it using the SMART RACE cDNA Amplification Kit from Clontech using SMART II oligonucleotide. PCR conditions were changed to 94°C for 5 minutes, followed by 5 cycles of 94°C for 30 seconds and 72°C for 2 minutes. Five cycles of 94°C for 30 seconds, 70°C for 45 seconds and 72°C for 2 minutes were performed next. The final 30 cycles were at 94°C for 30 seconds, 68°C for 45 seconds and 72°C for 2 minutes. The PCR was concluded with 72°C for 7 minutes.

20 Fragment 4: cDNA source - dog liver cDNA (SMART RACE) prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm3612FL	5'-gag gtg aag aag ggc cag acg ctg gcc ctc-3'	30mer	17	dog PGP1
RACE	5'-cta ata cga ctc act ata ggg caa gca gtg gta aca acg cag agt -3'		18	vector

This corresponds to a 3'end fragment of dog PGP from base 3212 to base 4264 in the open reading frame.

An RNA preparation from dog liver tissue was performed using the same method as used previously. cDNA was made from it using the SMART RACE cDNA Amplification Kit from Clontech using the gene specific Primer DM1680RL 5'-cgc agc cac tgt tcc caa cca gcg cca ct-3', 29mer, SEQ ID NO:19, dog PGP1.

Fragment 5: cDNA source - dog liver cDNA (SMART RACE with internal primer) prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dp409F	5'-gga gcg cga ggt cgg gat gga tc- 3'	23mer	20	human PGP1
Dm1355RL	5'-gga gag gac caa gga ggt ccc ata cca gaa a-3'	31mer	21	dog PGP1

This corresponds to an ATG fragment of dog PGP from base -15 to base 945 in the open reading frame.

Assembly of Clones

1Kb fragment (890bp) and 981bp fragment

DNA preps were made of each fragment. Both fragments were cut with NcoI restriction enzyme. The 1Kb fragment was also cut with EcoRI. The 981bp fragment was also cut with BamHI. Each fragment was purified, ligated together, then the ends were cut, the cut molecule was gel purified and ligated into pUC19 cut with EcoRI and BamHI.

1Kb fragment (890bp)/981bp fragment and 1728bp fragment

These fragments were assembled as above except that both fragments were cut with BamHI and the 1728bp fragment was also cut with XbaI.

1Kb fragment (890bp)/981bp fragment/1728bp fragment and ATG fragment
3'end and 779bp fragment

1Kb fragment (890bp)/981bp fragment/1728bp fragment ATG fragment and
3'end/779bp fragment

All of these fragments were assembled as above except that, in some cases, the fragments were cut with different restriction enzymes according to their nucleotide sequences.

The nucleotide sequence of a dog P-glycoprotein is presented as SEQ ID NO:1. The coding sequence consists of nucleotides 17-3859, producing a polypeptide of 1281 amino acids (SEQ ID NO:2).

Example 2: Activity of dog P-glycoprotein

Materials and Methods

Dog PGP cDNA (SEQ ID NO:1) is introduced into a clonal population of LLC-PK1 cells in a vector that confers resistance to hygromycin B. LLC-PK1 cells are obtained from

the American Type Culture Collections and are propagated in Medium 199 supplemented to 7% with fetal bovine serum. LLC-PK1 cells are recloned prior to transfection in order to assure homogeneity of the cell population. Briefly, dog PGP cDNA is incorporated into the p222CMV vector. This vector is derived from the p220.2 episomal vector system based on the OriP sequences for Epstein Barr virus and the EBNA-1 gene product (Sugden et al., *Mol. Cell Biol.* 5:410-413, 1985; Yates et al., *Nature (Lond.)* 313: 812-815, 1985). The PGP cDNA is under the control of the cytomegalovirus (CMV) immediate early promoter. The vector confers resistance to hygromycin B. Cells (in 0.4 mL) and DNA (10 to 20 µg) were transfected by electroporation using a BTX Electro cell manipulator model 600 using a 2 mm gap cell, 100V, 2500 µF capacitance and 72 ohm resistance. After electroporation, the cells are plated in multiwell plates (48 well, Corning Costar) at 10% of confluence. One to two days after transfection hygromycin B is introduced at a final concentration of 400 to 600 µg/ml. Cells are refed every 2 to 4 days and are propagated in 400 to 600 µg/ml hygromycin B for 6 to 8 days at which point the bulk of the wild type cells are detached. The hygromycin B is reduced to 100 µg/ml and maintained in this concentration of hygromycin B. After 14 to 18 days the wells are inspected and wells containing single colonies are trypsinized and scaled up to bulk cultures. Expression of PGP is measured by the polarization of vinblastine (0.1 uM) transport in Transwells™.

LLC-PK1 cell based transport studies are conducted in 24 well Transwells™ (Corning Costar, Catalog number 3415). Transwells™ are prepared by the addition of 0.6 mL media to the basolateral space and 0.1 mL media to the apical space. Cells are seeded at 4×10^4 cells per insert (typically in 0.05 mL to 0.15 mL), refed with fresh media every 2 to 4 days and used for transport studies 4 to 8 days post seeding. Transport assays are conducted in Hank's balanced saline (HBSS) buffered with 10 mM HEPES (pH 7 to 7.2). Cell monolayers are rinsed with HBSS prior to use in transport assays. Transport is measured under sink conditions in both the apical to basolateral (A to B) and basolateral to apical (B to A) directions. At least duplicate monolayers are used per determination. At the desired time points, samples are withdrawn from the receiver chamber (apical or basolateral chambers). Quantitation of the amount of compound transported is by liquid scintillation counting (vinblastine) or HPLC with UV or mass spectrometric detection.

Dog PGP cDNA is expressed in insect cells using a baculovirus vector. Membranes are prepared according to the method of (Sarkadi et al., *J. Biol. Chem.* 267: 4854-4858, 1992)

and stored at -80°C until use. ATPase assays are conducted in 96 well microtiter plates. The assays are conducted using a modification of the methods of (Sarkadi et al., 1992 and Druekes et al., *Anal. Biochem.* 230: 173-177, 1995).

A detailed method for each well of a 96 well plate is contained below:

5 A 0.06 ml reaction mixture containing 40 µg membranes, 20 µM Verapamil (positive control) or test drug, and 3-5 mM MgATP, in buffer containing 50 mM Tris-MES, 2 mM EGTA, 50 mM KCl, 2 mM dithiothreitol, and 5 mM sodium azide, is incubated at 37°C for 20 min. An identical reaction mixture containing 100 µM sodium orthovanadate is assayed in parallel. Orthovanadate inhibits PGP by trapping MgADP in the nucleotide binding site. Thus,
10 ATPase activity measured in the presence of orthovanadate represents non-PGP ATPase activity and can be subtracted from the activity generated without orthovanadate to yield vanadate-sensitive ATPase activity. The reaction is stopped by the addition of 30 µl of 10 % SDS + Antifoam A. Two additional reaction mixtures (+ and - orthovanadate) but without MgATP, are also prepared and incubated with the others, and then supplemented with SDS
15 and MgATP, to represent time = 0 min of reaction. The incubations are followed with addition of 200 µl of 35 mM ammonium molybdate in 15 mM zinc acetate:10 % ascorbic acid (1:4) and incubated for an additional 20 min at 37°C. The liberation of inorganic phosphate is detected by its absorbance at 800 nm and quantitated by comparing the absorbance to a phosphate standard curve.

20 Ligand binding assays and assays for measuring inhibition of fluorescent dye uptake are preformed as described by Sharom et al. (*Biochem. Pharmacol.* 58:571-586, 1999).

I. Stable PGP Expression in LLC-PK1 Cells.

Functional expression of dog PGP is measured by the polarization of transport of
25 vinblastine. Control cells typically demonstrate a B to A / A to B ratio of between 1 and 3. PGP transfected cells demonstrate a much higher ratio. The expression of cDNA-derived dog is stable.

II. Activation of ATPase Activity in PGP Membranes.

30 The stimulation of ATPase assay provides a rapid measure of the concentration dependence of any interaction of a drug with PGP. The liberated inorganic phosphate is measured by a simple spectrophotometric assay performed in a microtiter plate format. The

testing of multiple drug concentrations allows estimation of the affinity of the drug for PGP and whether saturation of the response was observed.

III. Drug Transport Across Cell Monolayers.

The ATPase assay does not directly measure drug transport. In order to examine the concordance between activation of ATPase and actual transport, the rates of transport of the drugs are measured in control LLC-PK1 and dog PGP cell monolayers. For each drug concentration, four measurements are made:

A:	A to B	Control cells
B:	B to A	Control cells
C:	A to B	PGP cells
D:	B to A	PGP cells

The polarization of transport is calculated in control cells (B/A) and PGP cells (D/C). The intrinsic activity (IA) of PGP is calculated as the sum of the amount PGP facilitated B to A transport in PGP cells relative to control cells (D minus B) and the amount that PGP impeded A to B transport in PGP cells relative to control cells (A minus C). The intrinsic clearance of PGP is calculated from a plot of the concentration dependence data by either calculating the slope of the line under non-saturating conditions or from the calculated apparent K_m and V_{max} values when saturation is observed. Intrinsic clearance is expressed as $mL/m^2/min$.

The ATPase data provides useful concentration response data. For example, the apparent K_m values for some compounds are in good agreement between the ATPase and transport systems. However, other drugs activate ATPase activity but transport by PGP is not detectable. At the least, ATPase assay can identify a concentration range below which the response to transport by PGP was linear with respect to drug concentration. This should allow simplification of the experimental design for measuring the intrinsic clearance of PGP, an important consideration if large numbers of compounds are to be tested.

IV. Bioavailability

Bioavailability studies are performed by performing one or more of the assays described above with two or more different PGP types. The different PGP types can be of different species (e.g., dog and human, cynomolgous monkey and human, dog and

cynomologous monkey, etc.) or can be different alleles of the same species. The results of these assays are compared to determine or estimate the bioavailability of a drug in individuals of the different species or in individuals that express different PGP alleles. The results of one determination also may be compared to a previously determined value of, e.g., ATPase or transport, as an historical control.

Protocols and Procedures

Isolation of RNA

Frozen beagle liver tissue was ground up using a mortar and pestle. Pulverized tissue (300 mg) was transferred to a dounce homogenizer. TRIzol Reagent (3mL; Cat. # 15596 from Life Technologies) was added and the tissue was homogenized then incubated for 15 minutes at room temperature. Aliquots (1mL) of the solution were transferred to three microfuge tubes and 200 μ L of chloroform were added to each tube. Each tube was vortexed at a high setting for 15 seconds, then incubated at room temperature for 3 minutes before being centrifuged at 10 000 g for 15 minutes at 4°C. The upper “aqueous” phase was transferred to a new microfuge tube while the remaining lower and inter phases were discarded. 500 μ L of Isopropanol was added to each of the new tubes and mixed by inverting the tube several times. Each tube was then incubated at room temperature for 10 minutes before being centrifuged at 10 000 g for 10 more minutes at 4°C. A small white pellet was observed and the supernatant was discarded. 1mL of 75% ethanol was added to each tube. The tubes were vortexed briefly then centrifuged at 10 000 g for 10 minutes at 4°C. The supernatant was discarded and the pellet dried for 5 minutes at room temperature. 50 μ L of DEPC treated sterile deionized water was added to each tube. Each pellet was resuspended and the contents of each tube were pooled.

Optical density of the resuspended pellet was analyzed using a Hitachi U3010 spectrophotometer to determine the quantity of RNA that was isolated. The RNA was then diluted using DEPC treated sterile deionized water to a concentration of 0.55 μ g/ μ L. 2 mL of this RNA was split evenly into 2 microfuge tubes. Next, 100 μ L of 5 M NaCl was added to each tube. Both tubes were heated to 65°C for 15 minutes, then put on ice for 5 minutes. 500 μ L of Oligo (dT) Cellulose Suspension from the MessageMaker mRNA Isolation System (Cat. # 10551-018 from Life Technologies) were added to both tubes. The tubes were then incubated at 37°C for 10 minutes. The contents of the tubes were transferred to the Filter

Syringe provided with the MessageMaker mRNA Isolation System. After expelling the liquid contents, the pellet in the syringe was washed using Wash Buffer 1 and Wash Buffer 2 according to the manufacturer's instructions. The RNA pellet in the syringe was resuspended in 1 mL of DEPC treated sterile deionized water (65°C), followed by the addition of 2.5 µL of 50 µg/mL glycogen and 100 µL of 7.5M ammonium acetate and mixing by inversion. The contents of the tube were then transferred to a two microfuge tubes and 1 mL of ethanol was added to each tube. The contents of both tubes were mixed by inversion, followed by incubation at -20°C overnight.

The tubes were centrifuged at 10 000 g for 30 minutes at 4°C. The supernatant was discarded and 200 µL of 75% ethanol was added to each tube. The tubes were vortexed for 10 seconds followed by centrifugation at 10 000 g for 15 minutes at 4°C. The supernatant was discarded and all remaining liquid was carefully pipetted off. The pellet was resuspended in 10 µL of DEPC treated sterile deionized water.

Preparation of cDNA

CDNA was prepared using the Marathon cDNA Amplification Kit (Cat. # K1802-1 from Clontech Laboratories, Inc., Palo Alto, CA) as follows. Four microliters of the resuspended mRNA were transferred to a new microfuge tube, and 1 µL of one of the following primers at 10 µM concentration was added: Dm1680RL cgc agc cac tgt tcc caa cca gcg cca ct (SEQ ID NO:19; custom designed, synthesized by Operon Technologies, Inc.) or cDNA Synthesis Primer, nnt ttt ttt ttt ttt ttt ttt ttt ttc gcc ggc gac tta aga tct t (SEQ ID NO:28), from the Marathon cDNA Amplification Kit. Tubes were incubated at 70°C for 2 minutes then placed on ice for 5 minutes. 2 µL of 5x First-Strand Buffer, 1 µL of 10mM dNTP Mix and 1 µL of 20 U/µL AMV Reverse Transcriptase were added to each tube and gently mixed. The tubes were incubated at 42°C for 1 hour, then placed on ice. 2 µL of each single stranded cDNA were used as template in PCR (see below, "PCR conditions"). 48.4 µL of DEPC treated deionized water, 16 µL of 5x Second-Strand Buffer, 1.6 µL of 10mM dNTP Mix and 4 µL of 20x Second-Strand Enzyme Cocktail were added to the remaining cDNA sample. The tube was incubated at 16°C for 1.5 hours. 2uL of 5U/uL T4 DNA Polymerase was added to the tube, which was then incubated at 16°C for an additional 45 minutes. 20x EDTA/Glycogen Mix (4 µL) was added followed by 430 µL of Buffer PN from the QIAquick Nucleotide Removal Kit (Cat. # 28304 from QIAGEN Inc., Valencia, CA). The sample was

then loaded into a QIAquick Spin Column and centrifuged at 10 000 g for 1 minute. The collection tube was emptied and 750 µL of PE Buffer (QIAGEN) were added to the QIAquick Spin Column which was again centrifuged at 10 000 g for 1 minute. The collection tube was once again emptied and the QIAquick Spin Column was centrifuged at 10 000 g for 1 minute to dry the column membrane. 50 µL of sterile deionized water heated to 50°C was added to the QIAquick Spin Column and incubated at room temperature for 1 minute before being centrifuged at 10 000 g for 1 minute into a clean microfuge tube.

To precipitate nucleic acid, 10.8 µL 7.5M ammonium acetate and 144 µL ethanol were added to the tube before it was centrifuged at 10 000 g for 20 minutes. The supernatant was removed, then 300 µL of 75% ethanol was added. The tube was vortexed and centrifuged at 10 000 g for 20 minutes. The supernatant was removed and the sample was resuspended in 12 µL of sterile deionized water. 5 µL of this cDNA were placed in a clean microfuge tube. 2 µL of 10 µM Marathon cDNA Adapter, 2 µL 5x DNA Ligation Buffer and 1 µL of 400U/µL T4 DNA Ligase, from the Marathon cDNA Amplification Kit, were added to the cDNA and mixed gently. This mixture was incubated over night at 16°C. The ligase was heat inactivated at 70°C for 5 minutes. PCR was done using this sample as a template.

PCR conditions

PCR was performed using reagents supplied with the Clontech Advantage 2 kit (Clontech, Palo Alto, CA). Briefly, 2 µL of cDNA was placed in a 200 µL MicroAmp reaction tube (Cat. # N801-0540, PE Biosystems), then 34 µL of sterile deionized water, 5 µL of 10x Clontech Advantage 2 Polymerase Mix (Cat. # 4700-1 Clontech Laboratories, Inc.), 3 µL of 10 mM Advantage UltraPure PCR Deoxynucleotide Mix (Cat. # 8430-1 Clontech Laboratories, Inc.) and 2 µL each of a forward and reverse primer at 10mM concentration were added. Primers were either Marathon cDNA Adapter Primer 1, cca tcc taa tac gac tca ctg tag ggc (SEQ ID NO:29), from the Marathon cDNA Amplification Kit or various custom gene specific primers made by Operon Technologies Inc. Custom primers include (all listed as 5'-3'): Dm409FL: gga gcg cga ggt cgg gat gga tc (SEQ ID NO:20), Dm1455RL: gca aat gct tca atg ctt ggg gat gcc tgt cca a (SEQ ID NO:30), Dm2037F: aga aac aga gaa tcg cca ttg ctc (SEQ ID NO:13), Dm3920RL: gag ctg ggt tcc ttt gtc tcc tac tct ggt gtt (SEQ ID NO:31), Dp1216F: gaa ctg tga ttg cgt ttg gag gac (SEQ ID NO:9), and Dp2587R: gca aat gct ggt tgc agg cct cc (SEQ ID NO:32).

Thermocycling was done using a Perkin Elmer 9700 at 94°C for 30 seconds followed by 2 cycles of 94°C for 5 seconds and 72°C for 4 minutes, followed by 16 cycles of 94°C for 5 seconds and 68°C for 4 minutes.

Four fragments were acquired by PCR for each Genotype. Fragment 1 was generated using primers Marathon cDNA Adapter Primer 1 and Dm1455RL. Fragment 2 was generated using primers Dp1216F and Dp2587R. Fragment 3 was generated using primers Dm2037F and Dm3920RL. Fragment 4 was generated using primers Dp3612FL and Marathon cDNA Adapter Primer 1.

Post PCR sample processing

Electrophoresis was performed on all PCR products using 10x Gel-loading Buffer IV (*Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, page 6.12), on a 1% agarose gel in 0.5x TBE buffer (Sambrook, et al., page B-23) containing EtBr. Fragments of gel containing the PCR products were cut out and placed in 2 mL microfuge tubes. The mass of each fragment was determined and 3 µL/mg of Buffer QX1 from QIAquick Gel Extraction Kit (Cat. # 28704 from QIAGEN Inc.) was added. Each tube was then incubated for 10 minutes at 50°C with mixture every two minutes. 1 µL/mg of isopropanol was added to each tube and mixed. The resulting solution was transferred to a QIAquick spin column from the QIAquick Gel Extraction Kit. These columns were centrifuged for 1 minute at 10 000 g at room temperature. 750 µL of Buffer PE from the QIAquick Gel Extraction Kit were added to each column followed by centrifugation for 1 minute at 10 000 g at room temperature. Each column was centrifuged again for 1 minute at 10 000 g at room temperature to remove any residual buffer. 30 µL of sterile deionized water at 50°C were added to each column and incubated for 1 minute at room temperature. Each column was then placed in a microfuge tube and centrifuged for 1 minute at 10 000 g.

Next, 6 µL of purified PCR product was transferred to a clean microfuge tube and 1 µL of 10x Ligation Buffer, 2 µL of pCR 2.1 vector and 1 µL of T4 DNA Ligase (all from the Original TA Cloning Kit (Cat. # K2000-J10) Invitrogen, Carlsbad, CA) were added to the microfuge tube and mixed. The reaction was incubated over night at 16°C.

One 50 µL vial of frozen One Shot competent cells (Invitrogen) was thawed on ice for each ligation reaction. 3.5 µL of ligation reaction mixture was added to the competent cells

and gently mixed. The cells incubated on ice for 30 minutes, followed by a 30 second “heat shock” at 42°C. After cooling on ice again, 250 µL of SOC medium (Invitrogen) was added to each vial and the vials were put directly into a 37°C water bath for 1 hour. 50 µL and 200 µL aliquots of each transformation reaction were plated on Luria-Bertani Medium (Sambrook et al., page A-1) containing 1% agarose, 1 mg/mL glucose, 50 ng/mL ampicillin and 1.6 ng/mL X-gal. The inoculated plates were then incubated at 37°C overnight. White colored colonies were selected and used to inoculate separate 100 mL cultures of L-B Medium containing 50 ng/mL ampicillin which were incubated at 37°C overnight while being stirred at 100 rpm.

Plasmid DNA was prepared using QIAGEN Midi Plasmid Kit (Cat. # 12143 from QIAGEN Inc.), according to the manufacturer’s instructions, as follows. Each 100 mL culture was aliquoted into two 50 mL conical vials and centrifuged at 3 000 g for 10 minutes at 4°C. The supernatant was poured off and 4 mL of Buffer P1 were used to resuspend the pellet in one of the two vials. This suspension was transferred to the other tube and used to resuspend that pellet. Buffer P2 (4 mL) was added, mixed and the suspension was incubated at room temperature for 5 minutes. Buffer P3 (4 mL) was added, mixed and the suspension was incubated at 4°C for 15 minutes. The samples were centrifuged at 3 000 g for 15 minutes at 4°C. All of the supernatant was transferred to a QIAGEN-tip 100 that had been previously treated with 4 mL of Buffer QBT. The supernatant was allowed to drain through the column. Buffer QC (10 mL) was added to the column and allowed to drain. Another 10 mL of Buffer QC was added and allowed to drain. Finally 4 mL of Buffer QF was added to the column and allowed to drain into a clean 15 mL conical vial. 2.8 mL of isopropanol was added and mixed with this solution. This was aliquoted into microfuge tubes, incubated at 4°C for 10 minutes and centrifuged at 10 000 g for 15 minutes at 4°C. The supernatant was removed, then 1 mL of 70% ethanol was added to each microfuge tube. Each tube was vortexed briefly, then centrifuged at 10 000 g for 15 minutes at 4°C. The supernatant was removed and 100 µL of sterile 1x TE buffer (Sambrook et al., page B-20) were added.

Restriction digests were performed on the purified DNA. Enzymes used to cut fragments out were: fragment 1, KpnI (Cat. # R0142S from New England Biolabs, Inc., Beverly, MA) and NsiI (Cat. # R0127S from New England Biolabs, Inc.); fragment 2, NsiI and HindIII (Cat. # R0104S from New England Biolabs, Inc.); fragment 3, HindIII and PstI (Cat. # V0279S from New England Biolabs, Inc.); and fragment 4, PstI and NotI (Cat. #

R0189S from New England Biolabs, Inc.). All restriction digests were performed at 37°C in digestion buffers recommended by New England Biolabs.

Electrophoresis was performed on all restriction digest products using 10x gel-loading buffer IV (Sambrook et al., page 6.12), on a 1% agarose gel in 0.5x TBE buffer (Sambrook et al., page B-23) containing EtBr. Fragments of gel containing the restriction digest products were cut out and placed in 2 mL microfuge tubes. DNA fragments were extracted from the gel slices using a QIAquick Gel Extraction Kit (Cat. # 28704 from QIAGEN Inc.) according to the manufacturer's instructions. The mass of each fragment was determined and 3 µL/mg of Buffer QX1 was added. Each tube was then incubated for 10 minutes at 50°C with mixture every two minutes. One volume of isopropanol was added to each tube and mixed. The resulting solution was transferred to a QIAquick spin column and centrifuged for 1 minute at 10 000 g at room temperature. Buffer PE (750 µL) was added to each column followed by centrifugation for 1 minute at 10 000 g at room temperature. Each column was centrifuged again for 1 minute at 10 000 g at room temperature to remove any residual buffer. 30 µL of sterile deionized water at 50°C was added to each column and incubated for 1 minute at room temperature. Each column was then placed in a microfuge tube and centrifuged for 1 minute at 10 000 g.

Two microliters of each fragment was added to a microfuge tube as well as 1 µL of 10x Ligation Buffer and 1 µL of T4 DNA Ligase (Cat. # M0202S from New England Biolabs, Inc.). This reaction was incubated at 16 °C overnight. Restriction enzymes KpnI and NotI (1 µL each) were added to the reaction and incubated at 37°C for 1 hour. Electrophoresis was performed using 10x Gel-loading Buffer IV on a 1% agarose gel in 0.5x TBE buffer containing EtBr. The fragment of gel containing the assembled product was cut out and the DNA fragment was extracted using a QIAquick Gel Extraction Kit as described above.

The fragment was ligated into a vector using an Original TA Cloning Kit, as follows: 6 µL of purified DNA were transferred to a clean microfuge tube and 1 µL of 10x Ligation Buffer, 2 µL of pCR 2.1 vector (previously digested with KpnI and NotI), and 1 µL of T4 DNA Ligase were added and mixed. The reaction was incubated over night at 16°C. The ligation reaction mixture (3.5 µL) was used to transform One Shot competent cells as described above, 50 µL and 200 µL aliquots of the transformation reaction were plated on Luria-Bertani Medium containing 1% agarose, 1mg/mL Glucose, 50ng/mL Ampicillin and 1.6ng/mL X-gal and grown as described above. White colored colonies were selected and

grown as described above. Plasmid DNA was isolated and purified using a QIAGEN Midi Plasmid Kit as described above. DNA was resuspended in 100 µL of sterile 1x TE buffer. This DNA was then sequenced using ABI 100 DNA sequencer (from ABI) by Tufts University Core Facility.

Identification of Four Genotypes of Dog P-glycoprotein

The dog P-glycoprotein identified in Example 1 is now termed genotype C. Sequencing of the DNA isolated from beagle liver as described in this example permitted the identification of three additional allelic variants of dog P-glycoprotein, termed genotypes A, B and D. the allelic differences in DNA sequence are set forth in Table 1 below.

Table 1: Nucleotide and Amino Acid Differences Between Dog P-glycoprotein Genotypes (Allelic Variants)

SEQ ID NO:		Genotype	Nucleotide position				Amino acid position			
DNA	Protein		91	607	1001	3458	25	197	329	1148
22	23	A	T	A	T	A	N	Q	S	M
24	25	B	A	A	T	A	K	Q	S	M
1	2	C	T	C	T	A	N	H	S	M
26	27	D	A	A	A	G	K	Q	T	V

Genotype A has a different nucleotide at base number 607 relative to SEQ ID NO:2. This is a base change from C to A in the DNA sequence which causes an amino acid change from Histidine to Glutamine at amino acid 197. Genotype B has different nucleotides at base number 91 and 607 relative to SEQ ID NO:2. The base change at position 91 is from T to A and causes an amino acid change from Asparagine to Lysine at amino acid 25. Base change at position 607 is identical to that in Genotype A. Genotype D has different nucleotides at base number 91, 607, 1001 and 3458 relative to SEQ ID NO:2. Base changes at position 91 and 607 are identical to that in Genotype B. The base change at position 1001 is from T to A and causes an amino acid change from Serine to Threonine at amino acid 329. The base change at position 3458 is from A to G and causes an amino acid change from Methionine to Valine at amino acid 1148.

A previously identified dog P-glycoprotein (SEQ ID NOs:3 and 4; GenBank Accession number AF045016), has 13 nucleotide differences from the genotype C dog P-glycoprotein nucleotide sequence (SEQ ID NO:1). There is a 3 base deletion at base 89 to

base 91 (relative to SEQ ID NO:1) leaving out AAT which causes a deletion of amino acid 25 Asparagine. There is a base change from A to G at position 590 which causes an amino acid change from Isoleucine to Valine at amino acid 192. There is a base change from C to A at position 607 which causing an amino acid change from Histidine to Glutamine at amino acid 5 197. There is a base change from G to C at position 651 which causes an amino acid change from Arginine to Proline at amino acid 212. There is a base change from G to A at position 878 which causes an amino acid change from Glycine to Arginine at amino acid 288. There is, a base change from T to A at position 1001 which causes an amino acid change from Serine to Threonine at amino acid 329. There is a base change from A to G at position 1012 10 which does not cause an amino acid change. This is a silent point mutation at Glutamine, amino acid 332. There is a base change from A to G at position 1611 which causes an amino acid change from Glutamine to Arginine at amino acid 532. There is a base change from A to T at position 2098 which does not cause an amino acid change. This is a silent point mutation at Valine, amino acid 694. There is a base change from C to T at position 2102 which causes 15 an amino acid change from Proline to Serine at amino acid 696. There is a base change from C to T at position 3808 which does not cause an amino acid change. This is a silent point mutation at Alanine, amino acid 1264. There is a base change from G to A at position 3833 which causes an amino acid change from Valine to Isoleucine at amino acid 1273. There is a base change from C to T at position 4080 which causes an amino acid change from Threonine 20 to Isoleucine at amino acid 1355.

Each of the foregoing patents, patent applications and references is hereby incorporated by reference. While the invention has been described with respect to certain embodiments, it should be appreciated that many modifications and changes may be made by 25 those of ordinary skill in the art without departing from the spirit of the invention. It is intended that such modification, changes and equivalents fall within the scope of the following claims.

What is claimed is:

Claims

1. An isolated nucleic acid molecule selected from the group consisting of
(a) nucleic acid molecules that code for the amino acid sequence of SEQ ID NO:2,
5 (b) allelic variants of (a), wherein the allelic variants exclude SEQ ID NO:3 and SEQ
ID NO:5, and
(c) complements of (a) or (b).

2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid
10 molecule codes for SEQ ID NO:2.

3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid
comprises the nucleotide sequence of SEQ ID NO:1.

4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid
15 comprises the coding region of SEQ ID NO:1.

5. The isolated nucleic acid molecule of claim 1, wherein the allelic variants are nucleic
acid molecules that code for an amino acid sequence selected from the group consisting of
20 SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27.

6. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for
SEQ ID NO:23.

7. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for
25 SEQ ID NO:25.

8. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for
SEQ ID NO:27.

9. The isolated nucleic acid molecule of claim 5, wherein the nucleic acid molecule
30 comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:22, SEQ

ID NO:24 and SEQ ID NO:26.

10. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:22.

5

11. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:24.

10

12. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:26.

13. The isolated nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a coding region of a nucleotide sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26.

15

14. An isolated P-glycoprotein polypeptide or fragment thereof which comprises at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 25, 192, 197, 212, 288, 329, 532, 696, 1273 and 1355 of SEQ ID NO:2; amino acid 25 of SEQ ID NO:25; and amino acids 25 and 1148 of SEQ ID NO:27.

20

15. An isolated P-glycoprotein polypeptide or fragment thereof which comprises at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 3, 6, 8, 10, 12, 14-26, 36, 38, 48, 52, 56, 64, 74, 78, 84-92, 94, 96, 98, 99, 101, 103, 104, 106, 108, 112, 115, 147, 187, 197, 199, 233, 288, 321, 326, 347, 397, 450, 454, 455, 467, 472, 520, 633, 637, 643, 644, 650, 657, 658, 661, 666, 667, 674-677, 679, 685, 689, 691, 693, 694, 703, 707, 717, 731, 736, 740, 744, 745, 756, 759, 763, 853, 914, 920, 942, 943, 946, 968-970, 972, 974, 983, 1005, 1010, 1017, 1025, 1026, 1029, 1040, 1095, 1098, 1105, 1144, 1148, 1149, 1158, 1162, 1165, 1168, 1170, 1252 and 1279 of SEQ ID NO:2; and amino acid 329 of SEQ ID NO:27, wherein the P-glycoprotein is identical to a human P-glycoprotein except for the at least one amino acid of a dog P-glycoprotein.

25

30

16. The isolated P-glycoprotein polypeptide or fragment thereof of claim 15, wherein the

human P-glycoprotein is selected from the group of SEQ ID NO:7 and SEQ ID NO:8.

17. The isolated P-glycoprotein polypeptide or fragment thereof of any of claims 14-16, wherein the amino acid sequence of the polypeptide or fragment thereof is an amino acid
5 sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, fragments of SEQ ID NO:2, fragments of SEQ ID NO:23, fragments of SEQ ID NO:25 and fragments of SEQ ID NO:27.

18. An isolated nucleic acid molecule which encodes the isolated P-glycoprotein
10 polypeptide or fragment thereof of any of claims 14-17.

19. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.

20. An expression vector comprising the isolated nucleic acid molecule of claim 18 operably linked to a promoter.

21. A host cell transformed or transfected with the expression vector of claim 19.

22. A host cell transformed or transfected with the expression vector of claim 20.

23. An agent which selectively binds the isolated polypeptide of claim 14.

24. The method of claim 23, wherein the agent does not bind a human or dog P-
25 glycoprotein.

25. The agent of claim 23, wherein the agent is a polypeptide.

26. The agent of claim 25, wherein the polypeptide is selected from the group consisting
30 of monoclonal antibodies, polyclonal antibodies, Fab antibody fragments, F(ab)₂ antibody fragments and antibody fragments including a CDR3 region.

27. An agent which selectively binds the isolated nucleic acid molecule of claim 1 or claim 18.

28. The agent of claim 27, wherein the agent is an antisense nucleic acid which selectively binds to the isolated nucleic acid molecule.

29. A method for predicting the bioavailability of a compound, comprising measuring the transmembrane transport of a test compound by a first P-glycoprotein, comparing the transmembrane transport of the test compound by the first P-glycoprotein and a second P-glycoprotein to predict the bioavailability of the test compound, wherein the relative amount or rate of transport by the first P-glycoprotein and the second P-glycoprotein is predictive of bioavailability of the test compound.

30. The method of claim 29, wherein the first P-glycoprotein is selected from the group consisting of dog P-glycoproteins and primate P-glycoproteins.

31. The method of claim 29, wherein the first P-glycoprotein is the polypeptide of claims 14-17.

32. The method of claim 29, wherein the second P-glycoprotein is a human P-glycoprotein.

33. A method for inhibiting P-glycoprotein transporter activity in a mammalian cell comprising contacting the mammalian cell with an amount of the agent of claim 27 effective to inhibit P-glycoprotein transporter activity in the mammalian cell.

34. A method for increasing bioavailability of a drug in a subject comprising administering to a subject in need of such treatment the agent of claim 27 in an amount effective to increasing bioavailability of a drug.

35. The method of claim 34, wherein the inhibitor is administered prior to administering

the drug.

36. The method of claim 34, wherein the inhibitor is administered concurrently with the drug.

37. A method for increasing P-glycoprotein transporter activity in a cell comprising contacting the cell with a molecule selected from the group consisting of the nucleic acid molecule of claim 1 and the nucleic acid molecule of claim 18, in an amount effective to increase P-glycoprotein transporter activity in the cell.

38. A method for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with P-glycoprotein transporter activity comprising providing a cell or other membrane-encapsulated space comprising a P-glycoprotein as claimed in claim 14 or 15;

contacting the cell or other membrane-encapsulated space with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of P-glycoprotein transporter activity;

determining a second amount of P-glycoprotein transporter activity as a measure of the effect of the pharmacological agent on the P-glycoprotein transporter activity, wherein a second amount of P-glycoprotein transporter activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces P-glycoprotein transporter activity and wherein a second amount of P-glycoprotein transporter activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases P-glycoprotein transporter activity.

39. The method of claim 38, further comprising the step of loading the cell or other membrane-encapsulated space with a detectable compound, wherein the compound is detected as a measure of the P-glycoprotein transporter activity.

40. A method for identifying compounds which selectively bind a P-glycoprotein comprising,

contacting the P-glycoprotein claimed in claim 14 or 15 with a compound,
determining the binding of the compound to the P-glycoprotein.

41. The method of claim 40 further comprising determining the effect of the compound on
5 the P-glycoprotein transporter activity of the P-glycoprotein.

42. The method of claim 40 further comprising determining the effect of the compound on
the ATPase activity of the P-glycoprotein.

10 43. A method for determining ATPase activity of a P-glycoprotein comprising
contacting the host cell of claim 20 or 22, or a membrane fraction thereof, with
a test drug, and
measuring ATPase activity of the P-glycoprotein.

15 44. The method of claim 43, wherein the step of measuring ATPase activity is performed
at least twice at different times.

45. A method for determining transmembrane transport of a compound by a P-
glycoprotein, comprising
20 contacting the host cell of claim 20 or 22, or a membrane fraction thereof, with
a test drug, and
measuring transport of the test drug under sink conditions in at least one direction of
transport selected from the group consisting of the apical to basolateral direction and the
basolateral to apical direction.

25 46. The method of claim 45, wherein the step of measuring transport of the test drug is
performed at least twice at different times.

The invention pertains to dog P-glycoproteins and related P-glycoproteins which include dog-specific amino acids, as well as nucleic acids which encode those polypeptides.

10

SEQUENCE LISTING

5 <110> Stocker, Penny J.
Steimel-Crespi, Dorothy T.
Crespi, Charles L.
Rief, Timothy C
Patten, Christopher J.

10 <120> P-GLYCOPROTEINS AND USES THEREOF

<130> G0307/7017

15 <150> US 60/156,510
<151> 1999-09-28

<160> 32

20 <170> FastSEQ for Windows Version 3.0

<210> 1
<211> 4279
<212> DNA
25 <213> Canis familiaris

<220>
<221> CDS
<222> (17)...(3859)

30 <400> 1
ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag 52
Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu
1 5 10

35 aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa aat gag aag aaa 100
Lys Asn Phe Trp Lys Met Gly Lys Lys Ser Lys Lys Asn Glu Lys Lys
15 20 25

40 gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat 148
Glu Lys Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn
30 35 40

45 tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc 196
Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile
45 50 55 60

cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca 244
His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr
50 65 70 75

gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt 292
Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val
80 85 90

55 ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat 340
Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His
95 100 105

60 ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt 388

	Leu	Glu	Glu	Glu	Met	Thr	Thr	Tyr	Ala	Tyr	Tyr	Tyr	Ser	Gly	Ile	Gly	
	110						115					120					
5	gct	ggc	gtg	ctg	gtg	gct	gct	tac	atc	cag	gtt	tca	ttc	tgg	tgc	ctg	436
	Ala	Gly	Val	Leu	Val	Ala	Ala	Tyr	Ile	Gln	Val	Ser	Phe	Trp	Cys	Leu	
	125					130				135						140	
10	gca	gca	gga	aga	cag	ata	ctc	aaa	att	aga	aaa	caa	ttt	ttt	cat	gct	484
	Ala	Ala	Gly	Arg	Gln	Ile	Leu	Lys	Ile	Arg	Lys	Gln	Phe	Phe	His	Ala	
					145					150					155		
15	atc	atg	cga	cag	gag	att	ggc	tgg	ttt	gac	gtg	cat	gac	gtt	ggg	gag	532
	Ile	Met	Arg	Gln	Glu	Ile	Gly	Trp	Phe	Asp	Val	His	Asp	Val	Gly	Glu	
				160					165					170			
	ctt	aac	acc	cgg	ctc	aca	gac	gat	gtc	tcc	aaa	atc	aat	gaa	gga	att	580
	Leu	Asn	Thr	Arg	Leu	Thr	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Gly	Ile	
			175					180					185				
20	ggc	gac	aaa	att	gga	atg	ttc	ttt	cac	tca	ata	gca	aca	ttt	ttc	acc	628
	Gly	Asp	Lys	Ile	Gly	Met	Phe	Phe	His	Ser	Ile	Ala	Thr	Phe	Phe	Thr	
		190					195					200					
25	ggc	ttt	ata	gtg	ggg	ttt	aca	cgt	ggc	tgg	aag	cta	acc	ctt	gtg	att	676
	Gly	Phe	Ile	Val	Gly	Phe	Thr	Arg	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile	
	205				210					215					220		
30	ttg	gcc	atc	agc	cct	gtt	ctt	gga	ctt	tca	gcc	gcc	atc	tgg	gca	aag	724
	Leu	Ala	Ile	Ser	Pro	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys	
					225					230					235		
35	ata	cta	tct	tca	ttt	act	gat	aaa	gaa	ctc	ttg	gcc	tat	gca	aaa	gct	772
	Ile	Leu	Ser	Ser	Phe	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	
				240				245						250			
40	gga	gca	gta	gct	gaa	gaa	gtc	tta	gca	gca	atc	aga	act	gtg	att	gcc	820
	Gly	Ala	Val	Ala	Glu	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	
			255				260						265				
45	ttt	gga	gga	caa	aag	aaa	gaa	ctt	gaa	agg	tac	aac	aaa	aat	tta	gaa	868
	Phe	Gly	Gly	Gln	Lys	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	
		270					275					280					
50	gaa	gct	aaa	gga	att	ggg	ata	aag	aaa	gct	atc	acg	gcc	aac	att	tct	916
	Glu	Ala	Lys	Gly	Ile	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	
		285				290					295					300	
55	att	ggc	gcc	gct	ttc	tta	ttg	atc	tat	gca	tca	tat	gct	ctg	gct	ttc	964
	Ile	Gly	Ala	Ala	Phe	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	
					305					310					315		
60	tgg	tat	ggg	acc	tcc	ttg	gtc	ctc	tcc	agt	gaa	tat	tct	att	gga	caa	1012
	Trp	Tyr	Gly	Thr	Ser	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Ser	Ile	Gly	Gln	
				320					325					330			
65	gta	ctc	act	gtc	ttc	ttt	tct	gta	tta	att	ggg	gct	ttt	agt	att	gga	1060
	Val	Leu	Thr	Val	Phe	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly	
			335					340					345				
70	cag	gca	tcc	cca	agc	att	gaa	gca	ttt	gca	aac	gca	aga	gga	gca	gct	1108

	Gln	Ala	Ser	Pro	Ser	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	
	350						355					360					
5	tat	gaa	atc	ttc	aag	ata	att	gac	aat	aaa	cca	agc	att	gac	agc	tat	1156
	Tyr	Glu	Ile	Phe	Lys	Ile	Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	
	365					370					375					380	
10	tcg	aag	agt	gga	cat	aaa	cca	gat	aat	att	aag	gga	aat	ttg	gaa	ttc	1204
	Ser	Lys	Ser	Gly	His	Lys	Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	
					385					390					395		
15	aaa	aat	gtt	cac	ttc	agt	tac	cct	tct	cga	aaa	gaa	gtt	aag	atc	tta	1252
	Lys	Asn	Val	His	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	
				400					405					410			
20	aag	ggt	ctc	aac	ctg	aag	gtt	cag	agt	ggg	cag	aca	gtg	gcg	ctg	gtt	1300
	Lys	Gly	Leu	Asn	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	
			415					420					425				
25	ggg	aac	agt	ggc	tgc	ggg	aag	agc	acg	acc	gtg	cag	ctg	atg	cag	agg	1348
	Gly	Asn	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	
		430					435					440					
30	ctc	tat	gac	ccc	aca	gat	ggc	atg	gtc	tgt	att	gat	gga	cag	gac	att	1396
	Leu	Tyr	Asp	Pro	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	
	445					450					455					460	
35	agg	acc	ata	aat	gta	agg	cat	ctt	cgg	gaa	att	act	ggt	gtg	gtg	agt	1444
	Arg	Thr	Ile	Asn	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	
					465					470					475		
40	cag	gag	cct	gtg	ttg	ttt	gcc	acc	acg	ata	gct	gaa	aac	att	cgc	tat	1492
	Gln	Glu	Pro	Val	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	
				480					485					490			
45	ggc	cgc	gaa	aat	gtc	acc	atg	gat	gag	att	gag	aaa	gct	gtt	aag	gaa	1540
	Gly	Arg	Glu	Asn	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	
			495					500					505				
50	gcc	aat	gcc	tat	gat	ttt	atc	atg	aaa	cta	cct	aat	aaa	ttt	gac	act	1588
	Ala	Asn	Ala	Tyr	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	
		510					515					520					
55	ctg	gtt	gga	gag	aga	ggg	gcc	cag	ctg	agt	ggt	gga	cag	aaa	cag	aga	1636
	Leu	Val	Gly	Glu	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	
	525					530					535					540	
60	atc	gcc	att	gct	cgg	gcc	ctg	gtt	cgc	aac	ccc	aag	att	ctt	ctg	ctg	1684
	Ile	Ala	Ile	Ala	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	
					545					550					555		
65	gat	gag	gca	acg	tca	gct	ctg	gac	act	gaa	agt	gaa	gca	gtg	gtt	cag	1732
	Asp	Glu	Ala	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	
				560					565					570			
70	gtg	gcc	ctg	gat	aag	gcc	aga	aaa	ggc	cgg	act	acc	att	gtg	ata	gct	1780
	Val	Ala	Leu	Asp	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	
			575					580					585				
75	cat	cgt	ttg	tct	aca	gtt	cgt	aat	gcc	gat	gtc	att	gct	ggt	ttt	gat	1828

	His	Arg	Leu	Ser	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	
	590						595					600					
5	gat	gga	gtc	att	gtg	gag	aaa	gga	aat	cat	gat	gaa	ctc	atg	aaa	gag	1876
	Asp	Gly	Val	Ile	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	
	605					610					615					620	
10	aag	ggc	att	tac	ttc	aaa	ctt	gtc	aca	atg	cag	aca	aga	gga	aat	gaa	1924
	Lys	Gly	Ile	Tyr	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	
					625					630					635		
15	att	gag	tta	gaa	aat	gcc	act	ggg	gaa	tcc	aaa	agt	gaa	agt	gat	gcc	1972
	Ile	Glu	Leu	Glu	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	
				640					645					650			
	ttg	gaa	atg	tct	cca	aaa	gat	tca	ggg	tcc	agt	tta	ata	aaa	aga	aga	2020
	Leu	Glu	Met	Ser	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	
			655					660					665				
20	tca	act	cgc	agg	agt	ata	cat	gca	cca	caa	ggc	caa	gac	aga	aag	ctt	2068
	Ser	Thr	Arg	Arg	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	
		670					675					680					
25	ggg	aca	aaa	gag	gac	ttg	aat	gag	aat	gta	cct	cca	ggt	tcc	ttc	tgg	2116
	Gly	Thr	Lys	Glu	Asp	Leu	Asn	Glu	Asn	Val	Pro	Pro	Val	Ser	Phe	Trp	
	685					690					695					700	
30	agg	att	ctg	aag	ctg	aac	tca	act	gaa	tgg	cct	tat	ttt	gtg	gtt	ggg	2164
	Arg	Ile	Leu	Lys	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	
					705					710					715		
35	ata	ttt	tgt	gct	att	ata	aac	gga	ggc	ctg	caa	cca	gca	ttt	tca	ata	2212
	Ile	Phe	Cys	Ala	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	
				720					725					730			
	ata	ttt	tca	agg	att	ata	ggg	atc	ttt	acc	cga	gat	gag	gat	cct	gaa	2260
	Ile	Phe	Ser	Arg	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	
			735					740					745				
40	aca	aaa	cga	cag	aat	agt	aac	atg	ttt	tct	gta	ttg	ttt	cta	gtc	ctt	2308
	Thr	Lys	Arg	Gln	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	
		750					755					760					
45	gga	att	att	tct	ttt	att	aca	ttt	ttc	ctc	cag	ggc	ttc	aca	ttt	ggc	2356
	Gly	Ile	Ile	Ser	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	
	765					770					775					780	
50	aaa	gct	ggg	gag	atc	ctc	act	aag	cgg	ctt	cga	tac	atg	gtt	ttc	aga	2404
	Lys	Ala	Gly	Glu	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	
					785					790					795		
55	tcc	atg	ctg	aga	cag	gat	gtc	agc	tgg	ttt	gat	gac	cct	aaa	aac	acc	2452
	Ser	Met	Leu	Arg	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	
				800					805					810			
	act	gga	gca	ttg	aca	acc	agg	ctt	gcc	aat	gat	gcg	gct	caa	gtt	aaa	2500
	Thr	Gly	Ala	Leu	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	
			815					820					825				
60	ggg	gct	ata	ggg	tcc	agg	ctt	gct	gtc	att	acc	cag	aat	ata	gca	aat	2548

	Gly	Ala	Ile	Gly	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	
	830						835					840					
5	ctt	ggg	aca	ggc	att	att	ata	tcc	tta	atc	tat	ggt	tgg	caa	tta	aca	2596
	Leu	Gly	Thr	Gly	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	
	845				850					855					860		
10	ctt	tta	ctc	tta	gca	att	gta	ccc	atc	att	gca	ata	gca	gga	gtt	gtt	2644
	Leu	Leu	Leu	Leu	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	
					865				870						875		
15	gaa	atg	aaa	atg	ttg	tct	gga	caa	gca	ctg	aaa	gat	aag	aaa	gag	cta	2692
	Glu	Met	Lys	Met	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	
				880				885						890			
20	gaa	gga	gct	ggg	aag	att	gct	aca	gaa	gcc	atc	gaa	aac	ttc	cga	act	2740
	Glu	Gly	Ala	Gly	Lys	Ile	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	
			895				900						905				
25	gtt	gtt	tct	ttg	act	cgg	gag	cag	aag	ttt	gaa	tac	atg	tat	gca	cag	2788
	Val	Val	Ser	Leu	Thr	Arg	Glu	Gln	Lys	Phe	Glu	Tyr	Met	Tyr	Ala	Gln	
	910						915					920					
30	agt	ttg	caa	gta	cca	tac	aga	aac	tct	ttg	agg	aaa	gca	cac	atc	ttc	2836
	Ser	Leu	Gln	Val	Pro	Tyr	Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	
	925					930					935					940	
35	ggg	gtc	tca	ttt	tct	atc	acc	cag	gca	atg	atg	tat	ttt	tcc	tat	gct	2884
	Gly	Val	Ser	Phe	Ser	Ile	Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	
				945						950					955		
40	ggc	tgt	ttc	cgg	ttt	ggg	gcc	tac	ttg	gtg	gca	aat	gag	ttc	atg	aac	2932
	Gly	Cys	Phe	Arg	Phe	Gly	Ala	Tyr	Leu	Val	Ala	Asn	Glu	Phe	Met	Asn	
				960				965						970			
45	ttt	cag	gat	gtt	ctt	ttg	gta	ttc	tca	gct	att	gtc	ttt	ggg	gcc	atg	2980
	Phe	Gln	Asp	Val	Leu	Leu	Val	Phe	Ser	Ala	Ile	Val	Phe	Gly	Ala	Met	
			975				980						985				
50	gca	gtg	ggg	cag	gtc	agt	tca	ttt	gct	cct	gac	tat	gcc	aaa	gcc	aaa	3028
	Ala	Val	Gly	Gln	Val	Ser	Ser	Phe	Ala	Pro	Asp	Tyr	Ala	Lys	Ala	Lys	
	990					995					1000						
55	gta	tca	gca	gcc	cac	gtc	atc	atg	atc	att	gaa	aaa	agc	cct	ctg	att	3076
	Val	Ser	Ala	Ala	His	Val	Ile	Met	Ile	Ile	Glu	Lys	Ser	Pro	Leu	Ile	
	1005					1010					1015					1020	
60	gac	agc	tac	agc	cct	cac	ggc	ctc	aag	cca	aat	acg	ttg	gaa	gga	aat	3124
	Asp	Ser	Tyr	Ser	Pro	His	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Glu	Gly	Asn	
				1025					1030					1035			
65	gtg	aca	ttt	aat	gag	gtc	gtg	ttc	aac	tat	ccc	act	cga	cca	gac	atc	3172
	Val	Thr	Phe	Asn	Glu	Val	Val	Phe	Asn	Tyr	Pro	Thr	Arg	Pro	Asp	Ile	
			1040					1045					1050				
70	ccc	gtg	ctc	cag	ggg	ctg	agc	ctc	gag	gtg	aag	aag	ggc	cag	acg	ctg	3220
	Pro	Val	Leu	Gln	Gly	Leu	Ser	Leu	Glu	Val	Lys	Lys	Gly	Gln	Thr	Leu	
			1055				1060					1065					
75	gcc	ctc	gta	ggg	agc	agt	ggc	tgt	ggg	aag	agc	aca	gtt	gtt	cag	ctc	3268

	Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu	
	1070 1075 1080	
5	cta gag cgc ttc tat gac ccc ttg gct ggt tca gtg cta att gat ggc Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly	3316
	1085 1090 1095 1100	
10	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly	3364
	1105 1110 1115	
15	atc gtg tct cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn	3412
	1120 1125 1130	
	att gcc tat gga gac aac agc cgg gtc gta tca cat gaa gag att atg Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met	3460
	1135 1140 1145	
20	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro	3508
	1150 1155 1160	
25	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly	3556
	1165 1170 1175 1180	
30	ggc cag aaa cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro	3604
	1185 1190 1195	
35	cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser	3652
	1200 1205 1210	
	gaa aag gtt gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr	3700
	1215 1220 1225	
40	tgc att gtg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu	3748
	1230 1235 1240	
45	ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln	3796
	1245 1250 1255 1260	
50	cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln	3844
	1265 1270 1275	
55	gct gga gca aag cgc tagtgaactg tggccatatg agctgttaaa tatttttttaa Ala Gly Ala Lys Arg	3899
	1280	
60	tatttgtgtt aaaacatggc atttaaatcaa agttaaagg tgagcactta ctggaaaaac tatgtagaac tacctgttta acatttcttg ctgcaactga agatcattcc accaagttca gagtcctcag attttataat taaaggaacc aaaagaaaca ttatctgatg gaataaaata ctgggtgttaa ttgcattata aaattataga gtaattcaaa gtagattttg ttaataaatt gtataatttt tgtttatatt ttatttgttaa cttactgctt tgctgaaaga ttatagaagt	3959 4019 4079 4139 4199

5	<div><210> 2</div> <div><211> 1281</div> <div><212> PRT</div> <div><213> Canis familiaris</div>															
10	<div><400> 2</div> <div>Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp</div> <div>1 5 10 15</div> <div>Lys Met Gly Lys Lys Ser Lys Lys Asn Glu Lys Lys Glu Lys Lys Pro</div> <div>20 25 30</div> <div>Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg</div> <div>35 40 45</div> <div>Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala</div> <div>50 55 60</div> <div>Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala</div> <div>65 70 75 80</div> <div>Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu</div> <div>85 90 95</div> <div>Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu</div> <div>100 105 110</div> <div>Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu</div> <div>115 120 125</div> <div>Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg</div> <div>130 135 140</div> <div>Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln</div> <div>145 150 155 160</div> <div>Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg</div> <div>165 170 175</div> <div>Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile</div> <div>180 185 190</div> <div>Gly Met Phe Phe His Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val</div> <div>195 200 205</div> <div>Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser</div> <div>210 215 220</div> <div>Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser</div> <div>225 230 235 240</div> <div>Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala</div> <div>245 250 255</div> <div>Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln</div> <div>260 265 270</div> <div>Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Gly</div> <div>275 280 285</div> <div>Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala</div> <div>290 295 300</div> <div>Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr</div> <div>305 310 315 320</div> <div>Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln Val Leu Thr Val</div> <div>325 330 335</div> <div>Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro</div> <div>340 345 350</div> <div>Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe</div> <div>355 360 365</div> <div>Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly</div> <div>370 375 380</div> <div>His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His</div> <div>385 390 395 400</div> <div>Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn</div>															

				405					410					415			
	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly	
				420					425					430			
5	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro	
			435					440					445				
	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	
		450				455						460					
	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	
	465					470				475						480	
10	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn	
				485						490					495		
	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	
			500						505					510			
15	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu	
		515						520					525				
	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	
		530					535					540					
	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Asp	Glu	Ala	Thr		
	545					550				555					560		
20	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp	
				565						570					575		
	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	
			580						585					590			
25	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile	
		595						600					605				
	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr	
		610					615					620					
	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	Glu	
	625					630					635					640	
30	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	Ser	
				645						650					655		
	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	Arg	
			660						665					670			
35	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	Glu	
		675						680					685				
	Asp	Leu	Asn	Glu	Asn	Val	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Leu	Lys	
		690					695					700					
	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	Ala	
	705					710				715					720		
40	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	Arg	
				725						730					735		
	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	Gln	
			740						745					750			
45	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	Ser	
		755						760					765				
	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu	
		770					775					780					
	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg	
	785					790					795				800		
50	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu	
				805						810					815		
	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly	
			820						825					830			
55	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly	
			835					840					845				
	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu	
		850					855					860					
	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	Met	
	865					870					875				880		
60	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	Gly	

885 890 895
 Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu
 900 905 910
 5 Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val
 915 920 925
 Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe
 930 935 940
 Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg
 945 950 955 960
 10 Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val
 965 970 975
 Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln
 980 985 990
 15 Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala
 995 1000 1005
 His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser
 1010 1015 1020
 Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn
 1025 1030 1035 104
 20 Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln
 1045 1050 1055
 Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly
 1060 1065 1070
 25 Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe
 1075 1080 1085
 Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys
 1090 1095 1100
 His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln
 1105 1110 1115 1120
 30 Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly
 1125 1130 1135
 Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys
 1140 1145 1150
 35 Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn
 1155 1160 1165
 Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln
 1170 1175 1180
 Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu
 1185 1190 1195 1200
 40 Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val
 1205 1210 1215
 Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile
 1220 1225 1230
 45 Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe
 1235 1240 1245
 Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala
 1250 1255 1260
 Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys
 1265 1270 1275 1280
 50 Arg

 55 <210> 3
 <211> 4317
 <212> DNA
 <213> Canis familiaris

 60 <220>
 <221> CDS
 <222> (70)...(3912)

<400> 3

	ctaagtcgga gtatcttctt cccaaattcc cttctcggtg gaggttgcca aggaaagccc	60
	gaggtgacg atg gat cct gaa gga ggc cgt aag ggg agt gca gag aag aac	111
5	Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn	
	1 5 10	
	ttc tgg aaa atg ggc aaa aaa agt aaa aaa gag aag aaa gaa aag aaa	159
10	Phe Trp Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Lys	
	15 20 25 30	
	cca act gtc agc acg ttt gca atg ttt cgc tat tca aat tgg ctt gat	207
	Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp	
	35 40 45	
15	agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc cat gga gct	255
	Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala	
	50 55 60	
20	gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca gat agc ttt	303
	Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe	
	65 70 75	
	gca aat gca gga att tca aga aac aaa act ttt cca gtt ata att aat	351
25	Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn	
	80 85 90	
	gaa agt att acg aac aat aca caa cat ttc atc aac cat ctg gag gag	399
	Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu	
	95 100 105 110	
30	gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt gct ggc gtg	447
	Glu Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val	
	115 120 125	
35	ctg gtg gct gct tac atc cag gtt tca ttc tgg tgc ctg gca gca gga	495
	Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly	
	130 135 140	
40	aga cag ata ctc aaa att aga aaa caa ttt ttt cat gct atc atg cga	543
	Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg	
	145 150 155	
	cag gag att ggc tgg ttt gac gtg cat gac gtt ggg gag ctt aac acc	591
45	Gln Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr	
	160 165 170	
	cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att ggc gac aaa	639
	Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys	
	175 180 185 190	
50	ggt gga atg ttc ttt caa tca ata gca aca ttt ttc acc ggt ttt ata	687
	Val Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile	
	195 200 205	
55	gtg ggg ttt aca cct ggt tgg aag cta acc ctt gtg att ttg gcc atc	735
	Val Gly Phe Thr Pro Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile	
	210 215 220	
60	agc cct gtt ctt gga ctt tca gcc gcc atc tgg gca aag ata cta tct	783

	Ser	Pro	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys	Ile	Leu	Ser	
			225					230					235				
5	tca	ttt	act	gat	aaa	gaa	ctc	ttg	gcc	tat	gca	aaa	gct	gga	gca	gta	831
	Ser	Phe	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	Gly	Ala	Val	
		240					245					250					
10	gct	gaa	gaa	gtc	tta	gca	gca	atc	aga	act	gtg	att	gcc	ttt	gga	gga	879
	Ala	Glu	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	Phe	Gly	Gly	
	255					260					265				270		
15	caa	aag	aaa	gaa	ctt	gaa	agg	tac	aac	aaa	aat	tta	gaa	gaa	gct	aaa	927
	Gln	Lys	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	Glu	Ala	Lys	
					275					280					285		
	aga	att	ggg	ata	aag	aaa	gct	atc	acg	gcc	aac	att	tct	att	ggt	gcc	975
	Arg	Ile	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	Ile	Gly	Ala	
				290					295				300				
20	gct	ttc	tta	ttg	atc	tat	gca	tca	tat	gct	ctg	gct	ttc	tgg	tat	ggg	1023
	Ala	Phe	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	Trp	Tyr	Gly	
			305					310					315				
25	acc	tcc	ttg	gtc	ctc	tcc	agt	gaa	tat	act	att	gga	cag	gta	ctc	act	1071
	Thr	Ser	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Thr	Ile	Gly	Gln	Val	Leu	Thr	
		320					325					330					
30	gtc	ttc	ttt	tct	gta	tta	att	ggg	gct	ttt	agt	att	gga	cag	gca	tcc	1119
	Val	Phe	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly	Gln	Ala	Ser	
	335					340					345					350	
35	cca	agc	att	gaa	gca	ttt	gca	aac	gca	aga	gga	gca	gct	tat	gaa	atc	1167
	Pro	Ser	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	Tyr	Glu	Ile	
					355					360					365		
	ttc	aag	ata	att	gac	aat	aaa	cca	agc	att	gac	agc	tat	tcg	aag	agt	1215
	Phe	Lys	Ile	Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	Ser	Lys	Ser	
				370					375					380			
40	gga	cat	aaa	cca	gat	aat	att	aag	gga	aat	ttg	gaa	ttc	aaa	aat	gtt	1263
	Gly	His	Lys	Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	Lys	Asn	Val	
			385					390					395				
45	cac	ttc	agt	tac	cct	tct	cga	aaa	gaa	gtt	aag	atc	tta	aag	ggt	ctc	1311
	His	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	
		400					405					410					
50	aac	ctg	aag	gtt	cag	agt	ggg	cag	aca	gtg	gcg	ctg	gtt	ggg	aac	agt	1359
	Asn	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	
	415					420					425				430		
55	ggc	tgc	ggg	aag	agc	acg	acc	gtg	cag	ctg	atg	cag	agg	ctc	tat	gac	1407
	Gly	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	
					435					440					445		
	ccc	aca	gat	ggc	atg	gtc	tgt	att	gat	gga	cag	gac	att	agg	acc	ata	1455
	Pro	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	
				450					455					460			
60	aat	gta	agg	cat	ctt	cgg	gaa	att	act	ggt	gtg	gtg	agt	cag	gag	cct	1503

	Asn	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	
			465					470					475				
5	gtg	ttg	ttt	gcc	acc	acg	ata	gct	gaa	aac	att	cgc	tat	ggc	cgc	gaa	1551
	Val	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	
		480					485					490					
10	aat	gtc	acc	atg	gat	gag	att	gag	aaa	gct	gtt	aag	gaa	gcc	aat	gcc	1599
	Asn	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	
	495					500					505					510	
15	tat	gat	ttt	atc	atg	aaa	cta	cct	aat	aaa	ttt	gac	act	ctg	gtt	gga	1647
	Tyr	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	
				515						520					525		
	gag	aga	ggg	gcc	cgg	ctg	agt	ggg	gga	cag	aaa	cag	aga	atc	gcc	att	1695
	Glu	Arg	Gly	Ala	Arg	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	
				530				535						540			
20	gct	cgg	gcc	ctg	gtt	cgc	aac	ccc	aag	att	ctt	ctg	ctg	gat	gag	gca	1743
	Ala	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	
			545					550					555				
25	acg	tca	gct	ctg	gac	act	gaa	agt	gaa	gca	gtg	gtt	cag	gtg	gcc	ctg	1791
	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	
		560					565					570					
30	gat	aag	gcc	aga	aaa	ggc	cgg	act	acc	att	gtg	ata	gct	cat	cgt	ttg	1839
	Asp	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	
	575					580					585					590	
35	tct	aca	gtt	cgt	aat	gcc	gat	gtc	att	gct	ggg	ttt	gat	gat	gga	gtc	1887
	Ser	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	
				595					600						605		
	att	gtg	gag	aaa	gga	aat	cat	gat	gaa	ctc	atg	aaa	gag	aag	ggc	att	1935
	Ile	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	
				610					615					620			
40	tac	ttc	aaa	ctt	gtc	aca	atg	cag	aca	aga	gga	aat	gaa	att	gag	tta	1983
	Tyr	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	
			625					630					635				
45	gaa	aat	gcc	act	ggg	gaa	tcc	aaa	agt	gaa	agt	gat	gcc	ttg	gaa	atg	2031
	Glu	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	
		640					645					650					
50	tct	cca	aaa	gat	tca	ggg	tcc	agt	tta	ata	aaa	aga	aga	tca	act	cgc	2079
	Ser	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	
	655					660					665					670	
55	agg	agt	ata	cat	gca	cca	caa	ggc	caa	gac	aga	aag	ctt	ggg	aca	aaa	2127
	Arg	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	
				675						680					685		
	gag	gac	ttg	aat	gag	aat	gtt	cct	tca	gtt	tcc	ttc	tgg	agg	att	ctg	2175
	Glu	Asp	Leu	Asn	Glu	Asn	Val	Pro	Ser	Val	Ser	Phe	Trp	Arg	Ile	Leu	
				690				695					700				
60	aag	ctg	aac	tca	act	gaa	tgg	cct	tat	ttt	gtg	gtt	ggg	ata	ttt	tgt	2223

	Lys	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	
			705					710					715				
5	gct	att	ata	aac	gga	ggc	ctg	caa	cca	gca	ttt	tca	ata	ata	ttt	tca	2271
	Ala	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	
		720					725					730					
10	agg	att	ata	ggg	atc	ttt	acc	cga	gat	gag	gat	cct	gaa	aca	aaa	cga	2319
	Arg	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	
	735					740					745					750	
15	cag	aat	agt	aac	atg	ttt	tct	gta	ttg	ttt	cta	gtc	ctt	gga	att	att	2367
	Gln	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	
					755					760					765		
	tct	ttt	att	aca	ttt	ttc	ctc	cag	ggc	ttc	aca	ttt	ggc	aaa	gct	ggg	2415
	Ser	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	
				770					775					780			
20	gag	atc	ctc	act	aag	cgg	ctt	cga	tac	atg	gtt	ttc	aga	tcc	atg	ctg	2463
	Glu	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	
			785					790					795				
25	aga	cag	gat	gtc	agc	tggt	ttt	gat	gac	cct	aaa	aac	acc	act	gga	gca	2511
	Arg	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	
		800					805					810					
30	ttg	aca	acc	agg	ctt	gcc	aat	gat	gcg	gct	caa	gtt	aaa	ggg	gct	ata	2559
	Leu	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	
	815					820					825					830	
35	ggt	tcc	agg	ctt	gct	gtc	att	acc	cag	aat	ata	gca	aat	ctt	ggg	aca	2607
	Gly	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	
					835					840					845		
	ggc	att	att	ata	tcc	tta	atc	tat	ggt	tggt	caa	tta	aca	ctt	tta	ctc	2655
	Gly	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	
				850					855					860			
40	tta	gca	att	gta	ccc	atc	att	gca	ata	gca	gga	gtt	gtt	gaa	atg	aaa	2703
	Leu	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	
			865					870					875				
45	atg	ttg	tct	gga	caa	gca	ctg	aaa	gat	aag	aaa	gag	cta	gaa	gga	gct	2751
	Met	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	
		880					885					890					
50	ggg	aag	att	gct	aca	gaa	gcc	atc	gaa	aac	ttc	cga	act	gtt	gtt	tct	2799
	Gly	Lys	Ile	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	
	895					900					905					910	
55	ttg	act	cgg	gag	cag	aag	ttt	gaa	tac	atg	tat	gca	cag	agt	ttg	caa	2847
	Leu	Thr	Arg	Glu	Gln	Lys	Phe	Glu	Tyr	Met	Tyr	Ala	Gln	Ser	Leu	Gln	
					915					920					925		
	gta	cca	tac	aga	aac	tct	ttg	agg	aaa	gca	cac	atc	ttc	ggg	gtc	tca	2895
	Val	Pro	Tyr	Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	Gly	Val	Ser	
				930					935					940			
60	ttt	tct	atc	acc	cag	gca	atg	atg	tat	ttt	tcc	tat	gct	ggc	tgt	ttc	2943

	Phe	Ser	Ile	Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	Gly	Cys	Phe	
			945					950					955				
5	cgg	ttt	ggt	gcc	tac	ttg	gtg	gca	aat	gag	ttc	atg	aac	ttt	cag	gat	2991
	Arg	Phe	Gly	Ala	Tyr	Leu	Val	Ala	Asn	Glu	Phe	Met	Asn	Phe	Gln	Asp	
		960					965					970					
10	ggt	ctt	ttg	gta	ttc	tca	gct	att	gtc	ttt	ggt	gcc	atg	gca	gtg	ggg	3039
	Val	Leu	Leu	Val	Phe	Ser	Ala	Ile	Val	Phe	Gly	Ala	Met	Ala	Val	Gly	
	975					980					985					990	
15	cag	gtc	agt	tca	ttt	gct	cct	gac	tat	gcc	aaa	gcc	aaa	gta	tca	gca	3087
	Gln	Val	Ser	Ser	Phe	Ala	Pro	Asp	Tyr	Ala	Lys	Ala	Lys	Val	Ser	Ala	
					995				1000						1005		
	gcc	cac	gtc	atc	atg	atc	att	gaa	aaa	agc	cct	ctg	att	gac	agc	tac	3135
	Ala	His	Val	Ile	Met	Ile	Ile	Glu	Lys	Ser	Pro	Leu	Ile	Asp	Ser	Tyr	
				1010					1015					1020			
20	agc	cct	cac	ggc	ctc	aag	cca	aat	acg	ttg	gaa	gga	aat	gtg	aca	ttt	3183
	Ser	Pro	His	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Glu	Gly	Asn	Val	Thr	Phe	
			1025					1030					1035				
25	aat	gag	gtc	gtg	ttc	aac	tat	ccc	act	cga	cca	gac	atc	ccc	gtg	ctc	3231
	Asn	Glu	Val	Val	Phe	Asn	Tyr	Pro	Thr	Arg	Pro	Asp	Ile	Pro	Val	Leu	
		1040					1045					1050					
30	cag	ggg	ctg	agc	ctc	gag	gtg	aag	aag	ggc	cag	acg	ctg	gcc	ctc	gta	3279
	Gln	Gly	Leu	Ser	Leu	Glu	Val	Lys	Lys	Gly	Gln	Thr	Leu	Ala	Leu	Val	
	1055					1060					1065					1070	
35	ggt	agc	agt	ggc	tgt	ggg	aag	agc	aca	gtt	gtt	cag	ctc	cta	gag	cgc	3327
	Gly	Ser	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Val	Val	Gln	Leu	Leu	Glu	Arg	
				1075					1080						1085		
	ttc	tat	gac	ccc	ttg	gct	ggg	tca	gtg	cta	att	gat	ggc	aaa	gag	ata	3375
	Phe	Tyr	Asp	Pro	Leu	Ala	Gly	Ser	Val	Leu	Ile	Asp	Gly	Lys	Glu	Ile	
				1090					1095					1100			
40	aag	cac	ctg	aat	gtc	cag	tgg	ctc	cga	gca	cac	ctg	ggc	atc	gtg	tct	3423
	Lys	His	Leu	Asn	Val	Gln	Trp	Leu	Arg	Ala	His	Leu	Gly	Ile	Val	Ser	
			1105				1110						1115				
45	cag	gag	ccc	atc	ctg	ttt	gac	tgc	agc	att	gcc	gag	aac	att	gcc	tat	3471
	Gln	Glu	Pro	Ile	Leu	Phe	Asp	Cys	Ser	Ile	Ala	Glu	Asn	Ile	Ala	Tyr	
		1120					1125					1130					
50	gga	gac	aac	agc	cgg	gtc	gta	tca	cat	gaa	gag	att	atg	cag	gca	gcc	3519
	Gly	Asp	Asn	Ser	Arg	Val	Val	Ser	His	Glu	Glu	Ile	Met	Gln	Ala	Ala	
	1135					1140					1145					1150	
55	aag	gag	gcc	aac	ata	cac	cac	ttc	atc	gag	aca	ctc	cct	gag	aaa	tac	3567
	Lys	Glu	Ala	Asn	Ile	His	His	Phe	Ile	Glu	Thr	Leu	Pro	Glu	Lys	Tyr	
				1155					1160						1165		
	aac	acc	aga	gta	gga	gac	aaa	gga	acc	cag	ctc	tct	ggt	ggc	cag	aaa	3615
	Asn	Thr	Arg	Val	Gly	Asp	Lys	Gly	Thr	Gln	Leu	Ser	Gly	Gly	Gln	Lys	
				1170					1175					1180			
60	cag	cgc	att	gcc	ata	gct	cgc	gct	ctt	gtt	aga	cag	cct	cat	att	ttg	3663

Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu
 1185 1190 1195

5	ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt gaa aag gtt Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val 1200 1205 1210	3711
10	gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc tgc att gtg Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val 1215 1220 1225 1230	3759
15	atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta ata gtg gtg Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val 1235 1240 1245	3807
	ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa cag ctg ctg Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu 1250 1255 1260	3855
20	gct cag aaa ggc atc tat ttt tcc atg atc agt gtc cag gct gga gca Ala Gln Lys Gly Ile Tyr Phe Ser Met Ile Ser Val Gln Ala Gly Ala 1265 1270 1275	3903
25	aag cgc tag tgaactgtgg ccatatgagc tggttaaatat tttttaatat Lys Arg 1280	3952
30	ttgtgttaaaa acatggcatt taatcaaagt taaaagggtga gcacttactg gaaaaactat gtagaactac ctgtttaaca tttcttgctg caactgaaga tcattccacc aagttcagag tcttcagatt ttataattaa aggaacaaaa agaaacatta tctgatggaa taaaatattg gtgttaattg cattataaaaa ttatagagta attcaaagta gatttttgta ataaattgta taatttttgt ttatatttta tttgtaactt actgctttgc tgaaagatta tagaagtggg aaaaagtact gaatgtttga ataaagtgc agctataata aaactaaaact tttatatgaa aaaaa	4012 4072 4132 4192 4252 4312 1
35	<210> 4 <211> 1280 <212> PRT <213> Canis familiaris	
40	<400> 4	
45	Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp 1 5 10 15 Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Lys Pro Thr 20 25 30 Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg Leu 35 40 45 Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala Leu 50 55 60 Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala Asn 65 70 75 80 Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu Ser 85 90 95 Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu Met 100 105 110 Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val 115 120 125 Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln 130 135 140 Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu	
50		
55		
60		

	625				630				635				640			
	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	Ser	Pro
					645					650					655	
5	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	Arg	Ser
				660					665					670		
	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	Glu	Asp
			675					680					685			
	Leu	Asn	Glu	Asn	Val	Pro	Ser	Val	Ser	Phe	Trp	Arg	Ile	Leu	Lys	Leu
		690					695					700				
10	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	Ala	Ile
	705					710					715					720
	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	Arg	Ile
					725					730					735	
15	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	Gln	Asn
				740					745					750		
	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	Ser	Phe
			755					760					765			
	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu	Ile
		770					775					780				
20	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg	Gln
	785					790					795					800
	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu	Thr
					805					810					815	
25	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly	Ser
				820					825					830		
	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly	Ile
		835					840						845			
	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu	Ala
		850					855					860				
30	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	Met	Leu
	865					870					875					880
	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	Gly	Lys
				885						890					895	
35	Ile	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	Leu	Thr
				900					905					910		
	Arg	Glu	Gln	Lys	Phe	Glu	Tyr	Met	Tyr	Ala	Gln	Ser	Leu	Gln	Val	Pro
		915						920					925			
	Tyr	Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	Gly	Val	Ser	Phe	Ser
		930					935					940				
40	Ile	Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	Gly	Cys	Phe	Arg	Phe
	945					950					955					960
	Gly	Ala	Tyr	Leu	Val	Ala	Asn	Glu	Phe	Met	Asn	Phe	Gln	Asp	Val	Leu
				965						970					975	
45	Leu	Val	Phe	Ser	Ala	Ile	Val	Phe	Gly	Ala	Met	Ala	Val	Gly	Gln	Val
				980					985					990		
	Ser	Ser	Phe	Ala	Pro	Asp	Tyr	Ala	Lys	Ala	Lys	Val	Ser	Ala	Ala	His
			995					1000					1005			
	Val	Ile	Met	Ile	Ile	Glu	Lys	Ser	Pro	Leu	Ile	Asp	Ser	Tyr	Ser	Pro
		1010					1015					1020				
50	His	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Glu	Gly	Asn	Val	Thr	Phe	Asn	Glu
	1025					1030					1035					1040
	Val	Val	Phe	Asn	Tyr	Pro	Thr	Arg	Pro	Asp	Ile	Pro	Val	Leu	Gln	Gly
				1045						1050					1055	
55	Leu	Ser	Leu	Glu	Val	Lys	Lys	Gly	Gln	Thr	Leu	Ala	Leu	Val	Gly	Ser
				1060					1065					1070		
	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Val	Val	Gln	Leu	Leu	Glu	Arg	Phe	Tyr
		1075						1080					1085			
	Asp	Pro	Leu	Ala	Gly	Ser	Val	Leu	Ile	Asp	Gly	Lys	Glu	Ile	Lys	His
		1090					1095					1100				
60	Leu	Asn	Val	Gln	Trp	Leu	Arg	Ala	His	Leu	Gly	Ile	Val	Ser	Gln	Glu

60

	agg agt ata cat gca cca caa ggc caa gac aga aag ctt ggt aca aaa	384
	Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys	
	115 120 125	
5	gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg agg att ctg	432
	Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu	
	130 135 140	
10	aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt ata ttt tgt	480
	Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys	
	145 150 155 160	
15	gct att ata aac gga ggc ctg cag cca gca ttt tca ata ata ttt tca	528
	Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser	
	165 170 175	
20	agg att ata ggg atc ttt acc cga gat gag gat cct gaa aca aaa cga	576
	Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg	
	180 185 190	
25	cag att agt aac atg ttt tct gta ttg ttt cta gtc ctt gga att att	624
	Gln Ile Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile	
	195 200 205	
30	tct ttt att aca ttt ttc ctt cag ggt ttc aca ttt ggc aaa gct gga	672
	Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly	
	210 215 220	
35	gag atc ctc act aag cgg ctt cga tac atg gtt ttc aga tcc atg ctg	720
	Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu	
	225 230 235 240	
40	aga cag gat gtc agc tgg ttt gat gac ctt aaa aac acc act gga gca	768
	Arg Gln Asp Val Ser Trp Phe Asp Asp Leu Lys Asn Thr Thr Gly Ala	
	245 250 255	
45	ttg acc acc agg ctt gcc aat gat gct gct caa gtt aaa ggg gct ata	816
	Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile	
	260 265 270	
50	ggt tcc agg ctt gct gtc att acc cag aat ata gca aat ctt ggg aca	864
	Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr	
	275 280 285	
55	ggc att att ata tcc tta atc tat ggt tgg caa tta aca ctt tta ctc	912
	Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu	
	290 295 300	
60	tta gca att gta ccc atc att gca ata gca gga gtt gtt gaa atg aaa	960
	Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys	
	305 310 315 320	
65	atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta gaa gga gct	1008
	Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala	
	325 330 335	
70	ggg aag att gct aca gaa gcc atc gaa aac ttc cga act gtt gtt tct	1056
	Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser	
	340 345 350	

ttg act cag gag cag aag ttt gaa cac atg tat gca cag agt ttg cag 1104
 Leu Thr Gln Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln
 355 360 365

5 gta 1107

<210> 6

<211> 368

<212> PRT

10 <213> Canis familiaris

<400> 6

Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu
 1 5 10 15
 15 Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu
 20 25 30
 Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val
 35 40 45
 20 Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile
 50 55 60
 Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu Ile Asp Leu
 65 70 75 80
 Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met
 85 90 95
 25 Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg
 100 105 110
 Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys
 115 120 125
 30 Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu
 130 135 140
 Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys
 145 150 155 160
 Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser
 165 170 175
 35 Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg
 180 185 190
 Gln Ile Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile
 195 200 205
 40 Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly
 210 215 220
 Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu
 225 230 235 240
 Arg Gln Asp Val Ser Trp Phe Asp Asp Leu Lys Asn Thr Thr Gly Ala
 245 250 255
 45 Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile
 260 265 270
 Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr
 275 280 285
 50 Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu
 290 295 300
 Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys
 305 310 315 320
 Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala
 325 330 335
 55 Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser
 340 345 350
 Leu Thr Gln Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln
 355 360 365

60 <210> 7

<211> 1280
 <212> PRT
 <213> Homo sapiens

5 <400> 7
 Met Asp Leu Glu Gly Asp Arg Asn Gly Gly Ala Lys Lys Lys Asn Phe
 1 5 10 15
 Phe Lys Leu Asn Asn Lys Ser Glu Lys Asp Lys Lys Glu Lys Lys Pro
 20 25 30
 10 Thr Val Ser Val Phe Ser Met Phe Arg Tyr Ser Asn Trp Leu Asp Lys
 35 40 45
 Leu Tyr Met Val Val Gly Thr Leu Ala Ala Ile Ile His Gly Ala Gly
 50 55 60
 Leu Pro Leu Met Met Leu Val Phe Gly Glu Met Thr Asp Ile Phe Ala
 15 65 70 75 80
 Asn Ala Gly Asn Leu Glu Asp Leu Met Ser Asn Ile Thr Asn Arg Ser
 85 90 95
 Asp Ile Asn Asp Thr Gly Phe Phe Met Asn Leu Glu Glu Asp Met Thr
 100 105 110
 20 Arg Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val Ala
 115 120 125
 Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile
 130 135 140
 His Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu Ile
 25 145 150 155 160
 Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr
 165 170 175
 Asp Asp Val Ser Lys Ile Asn Glu Val Ile Gly Asp Lys Ile Gly Met
 180 185 190
 30 Phe Phe Gln Ser Met Ala Thr Phe Phe Thr Gly Phe Ile Val Gly Phe
 195 200 205
 Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val
 210 215 220
 Leu Gly Leu Ser Ala Ala Val Trp Ala Lys Ile Leu Ser Ser Phe Thr
 35 225 230 235 240
 Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu
 245 250 255
 Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Lys Lys
 260 265 270
 40 Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Arg Ile Gly
 275 280 285
 Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala Phe Leu
 290 295 300
 Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Thr Leu
 45 305 310 315 320
 Val Leu Ser Gly Glu Tyr Ser Ile Gly Gln Val Leu Thr Val Phe Phe
 325 330 335
 Ser Val Leu Ile Gly Ala Phe Ser Val Gly Gln Ala Ser Pro Ser Ile
 340 345 350
 50 Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe Lys Ile
 355 360 365
 Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly His Lys
 370 375 380
 Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Arg Asn Val His Phe Ser
 55 385 390 395 400
 Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn Leu Lys
 405 410 415
 Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly
 420 425 430
 60 Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Thr Glu

			435					440					445				
	Gly	Met	Val	Ser	Val	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	Val	Arg	
		450					455					460					
5	Phe	Leu	Arg	Glu	Ile	Ile	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	Leu	Phe	
	465					470					475					480	
	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn	Val	Thr	
					485					490					495		
	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	Asp	Phe	
				500					505					510			
10	Ile	Met	Lys	Leu	Pro	His	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu	Arg	Gly	
			515					520					525				
	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	Arg	Ala	
		530					535					540					
15	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr	Ser	Ala	
	545					550					555					560	
	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp	Lys	Ala	
					565					570					575		
	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	Thr	Val	
				580					585					590			
20	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile	Val	Glu	
			595					600				605					
	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr	Phe	Lys	
		610					615					620					
25	Leu	Val	Thr	Met	Gln	Thr	Ala	Gly	Asn	Glu	Val	Glu	Leu	Glu	Asn	Ala	
	625					630					635					640	
	Ala	Asp	Glu	Ser	Lys	Ser	Glu	Ile	Asp	Ala	Leu	Glu	Met	Ser	Ser	Asn	
					645					650					655		
	Asp	Ser	Arg	Ser	Ser	Leu	Ile	Arg	Lys	Arg	Ser	Thr	Arg	Arg	Ser	Val	
				660					665					670			
30	Arg	Gly	Ser	Gln	Ala	Gln	Asp	Arg	Lys	Leu	Ser	Thr	Lys	Glu	Ala	Leu	
			675					680					685				
	Asp	Glu	Ser	Ile	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Met	Lys	Leu	Asn	
		690					695					700					
35	Leu	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Val	Phe	Cys	Ala	Ile	Ile	
	705					710					715					720	
	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ala	Ile	Ile	Phe	Ser	Lys	Ile	Ile	
					725					730					735		
	Gly	Val	Phe	Thr	Arg	Ile	Asp	Asp	Pro	Glu	Thr	Lys	Arg	Gln	Asn	Ser	
				740					745					750			
40	Asn	Leu	Phe	Ser	Leu	Leu	Phe	Leu	Ala	Leu	Gly	Ile	Ile	Ser	Phe	Ile	
			755					760					765				
	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu	Ile	Leu	
		770					775					780					
45	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg	Gln	Asp	
	785					790					795					800	
	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu	Thr	Thr	
					805					810					815		
	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly	Ser	Arg	
				820					825					830			
50	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly	Ile	Ile	
			835					840					845				
	Ile	Ser	Phe	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu	Ala	Ile	
		850					855					860					
55	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	Met	Leu	Ser	
	865					870					875					880	
	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	Gly	Lys	Ile	
					885					890					895		
	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	Leu	Thr	Gln	
				900					905					910			
60	Glu	Gln	Lys	Phe	Glu	His	Met	Tyr	Ala	Gln	Ser	Leu	Gln	Val	Pro	Tyr	

915 920 925
 Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Ile Thr Phe Ser Phe
 930 935 940
 Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg Phe Gly
 5 945 950 955 960
 Ala Tyr Leu Val Ala His Lys Leu Met Ser Phe Glu Asp Val Leu Leu
 965 970 975
 Val Phe Ser Ala Val Val Phe Gly Ala Met Ala Val Gly Gln Val Ser
 980 985 990
 10 Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Ile Ser Ala Ala His Ile
 995 1000 1005
 Ile Met Ile Ile Glu Lys Thr Pro Leu Ile Asp Ser Tyr Ser Thr Glu
 1010 1015 1020
 Gly Leu Met Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Gly Glu Val
 15 1025 1030 1035 1040
 Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly Leu
 1045 1050 1055
 Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser
 1060 1065 1070
 20 Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp
 1075 1080 1085
 Pro Leu Ala Gly Lys Val Leu Leu Asp Gly Lys Glu Ile Lys Arg Leu
 1090 1095 1100
 Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu Pro
 25 1105 1110 1115 1120
 Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn
 1125 1130 1135
 Ser Arg Val Val Ser Gln Glu Glu Ile Val Arg Ala Ala Lys Glu Ala
 1140 1145 1150
 30 Asn Ile His Ala Phe Ile Glu Ser Leu Pro Asn Lys Tyr Ser Thr Lys
 1155 1160 1165
 Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile
 1170 1175 1180
 Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp
 35 1185 1190 1195 1200
 Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu
 1205 1210 1215
 Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His
 1220 1225 1230
 40 Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln Asn
 1235 1240 1245
 Gly Arg Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys
 1250 1255 1260
 Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Thr Lys Arg Gln
 45 1265 1270 1275 1280

 <210> 8
 <211> 1279
 <212> PRT
 50 <213> Homo sapiens

 <400> 8
 Met Asp Leu Glu Gly Asp Arg Asn Gly Gly Ala Lys Lys Lys Asn Phe
 1 5 10 15
 55 Phe Lys Leu Asn Asn Lys Ser Glu Lys Asp Lys Lys Glu Lys Lys Pro
 20 25 30
 Thr Val Ser Val Phe Ser Met Phe Arg Tyr Ser Asn Trp Leu Asp Lys
 35 40 45
 Leu Tyr Met Val Val Gly Thr Leu Ala Ala Ile Ile His Gly Ala Gly
 60 50 55 60

	Leu	Pro	Leu	Met	Met	Leu	Val	Phe	Gly	Glu	Met	Thr	Asp	Ile	Phe	Ala
	65					70					75					80
	Asn	Ala	Gly	Asn	Leu	Glu	Asp	Leu	Met	Ser	Asn	Ile	Thr	Asn	Arg	Ser
				85						90					95	
5	Asp	Ile	Asn	Asp	Thr	Gly	Phe	Phe	Met	Asn	Leu	Glu	Glu	Asp	Met	Thr
			100						105					110		
	Arg	Tyr	Ala	Tyr	Tyr	Tyr	Ser	Gly	Ile	Gly	Ala	Gly	Val	Leu	Val	Ala
			115					120					125			
10	Ala	Tyr	Ile	Gln	Val	Ser	Phe	Trp	Cys	Leu	Ala	Ala	Gly	Arg	Gln	Ile
	130						135						140			
	His	Lys	Ile	Arg	Lys	Gln	Phe	Phe	His	Ala	Ile	Met	Arg	Gln	Glu	Ile
	145					150					155					160
	Gly	Trp	Phe	Asp	Val	His	Asp	Val	Gly	Glu	Leu	Asn	Thr	Arg	Leu	Thr
				165						170					175	
15	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Gly	Ile	Gly	Asp	Lys	Ile	Gly	Met
			180						185					190		
	Phe	Phe	Gln	Ser	Met	Ala	Thr	Phe	Phe	Thr	Gly	Phe	Ile	Val	Gly	Phe
			195					200					205			
20	Thr	Arg	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile	Leu	Ala	Ile	Ser	Pro	Val
	210						215					220				
	Leu	Gly	Leu	Ser	Ala	Ala	Val	Trp	Ala	Lys	Ile	Leu	Ser	Ser	Phe	Thr
	225					230					235					240
	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	Gly	Ala	Val	Ala	Glu	Glu
					245					250					255	
25	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	Phe	Gly	Gly	Gln	Lys	Lys
				260					265					270		
	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	Glu	Ala	Lys	Arg	Ile	Gly
				275				280					285			
30	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	Ile	Gly	Ala	Ala	Phe	Leu
	290					295						300				
	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	Trp	Tyr	Gly	Thr	Thr	Leu
	305					310					315					320
	Val	Leu	Ser	Gly	Glu	Tyr	Ser	Ile	Gly	Gln	Val	Leu	Thr	Val	Phe	Ser
					325					330					335	
35	Val	Leu	Ile	Gly	Ala	Phe	Ser	Val	Gly	Gln	Ala	Ser	Pro	Ser	Ile	Glu
				340					345					350		
	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	Tyr	Glu	Ile	Phe	Lys	Ile	Ile
				355				360					365			
40	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	Ser	Lys	Ser	Gly	His	Lys	Pro
	370						375					380				
	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	Arg	Asn	Val	His	Phe	Ser	Tyr
	385					390					395					400
	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	Asn	Leu	Lys	Val
					405					410					415	
45	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly	Cys	Gly	Lys
				420					425					430		
	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro	Thr	Glu	Gly
				435				440					445			
50	Met	Val	Ser	Val	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	Val	Arg	Phe
	450					455						460				
	Leu	Arg	Glu	Ile	Ile	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	Leu	Phe	Ala
	465					470					475					480
	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn	Val	Thr	Met
					485					490					495	
55	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	Asp	Phe	Ile
				500					505					510		
	Met	Lys	Leu	Pro	His	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu	Arg	Gly	Ala
			515					520					525			
60	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	Arg	Ala	Leu
	530						535					540				

[illegible]

Leu Met Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Gly Glu Val Val
 1025 1030 1035 1040
 Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly Leu Ser
 1045 1050 1055
 5 Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser Gly
 1060 1065 1070
 Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp Pro
 1075 1080 1085
 10 Leu Ala Gly Lys Val Leu Leu Asp Gly Lys Glu Ile Lys Arg Leu Asn
 1090 1095 1100
 Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu Pro Ile
 1105 1110 1115 1120
 Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn Ser
 1125 1130 1135
 15 Arg Val Val Ser Gln Glu Glu Ile Val Arg Ala Ala Lys Glu Ala Asn
 1140 1145 1150
 Ile His Ala Phe Ile Glu Ser Leu Pro Asn Lys Tyr Ser Thr Lys Val
 1155 1160 1165
 20 Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala
 1170 1175 1180
 Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp Glu
 1185 1190 1195 1200
 Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu Ala
 1205 1210 1215
 25 Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His Arg
 1220 1225 1230
 Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln Asn Gly
 1235 1240 1245
 30 Arg Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys Gly
 1250 1255 1260
 Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Thr Lys Arg Gln
 1265 1270 1275

 35 <210> 9
 <211> 24
 <212> DNA
 <213> Homo sapiens

 40 <400> 9
 gaactgtgat tgcgtttgga ggac 24

 <210> 10
 <211> 22
 <212> DNA
 45 <213> Canis familiaris

 <400> 10
 ttcagggccg cctgtacctc tg 22

 50 <210> 11
 <211> 22
 <212> DNA
 <213> Canis familiaris

 55 <400> 11
 cccacagat ggcatggtct gt 22

 <210> 12
 <211> 23
 60 <212> DNA

<213> Homo sapiens
 <400> 12
 5 cgcttggtga ggatctctcc agc 23
 <210> 13
 <211> 24
 <212> DNA
 10 <213> Canis familiaris
 <400> 13
 agaaacagag aatcgccatt gctc 24
 <210> 14
 15 <211> 23
 <212> DNA
 <213> Homo sapiens
 <400> 14
 20 gctgcagtca aacaggatgg gct 23
 <210> 15
 <211> 24
 <212> DNA
 25 <213> Canis familiaris
 <400> 15
 agttcatttg ctcttgacta tgcc 24
 <210> 16
 30 <211> 22
 <212> DNA
 <213> Homo sapiens
 <400> 16
 35 gatgcctttc tgggccagca gc 22
 <210> 17
 40 <211> 30
 <212> DNA
 <213> Canis familiaris
 <400> 17
 45 gaggtgaaga agggccagac gctggccctc 30
 <210> 18
 <211> 45
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 <223> Synthetic oligonucleotide
 <400> 18
 55 ctaatacgac tcactatagg gcaagcagtg gtaacaacgc agagt 45
 <210> 19
 <211> 29
 <212> DNA
 60 <213> Canis familiaris

60

	110				115				120								
5	gct	ggc	gtg	ctg	gtg	gct	gct	tac	atc	cag	gtt	tca	ttc	tgg	tgc	ctg	436
	Ala	Gly	Val	Leu	Val	Ala	Ala	Tyr	Ile	Gln	Val	Ser	Phe	Trp	Cys	Leu	
	125					130					135					140	
10	gca	gca	gga	aga	cag	ata	ctc	aaa	att	aga	aaa	caa	ttt	ttt	cat	gct	484
	Ala	Ala	Gly	Arg	Gln	Ile	Leu	Lys	Ile	Arg	Lys	Gln	Phe	Phe	His	Ala	
					145					150					155		
15	atc	atg	cga	cag	gag	att	ggc	tgg	ttt	gac	gtg	cat	gac	ggt	ggg	gag	532
	Ile	Met	Arg	Gln	Glu	Ile	Gly	Trp	Phe	Asp	Val	His	Asp	Val	Gly	Glu	
				160					165					170			
20	ctt	aac	acc	cgg	ctc	aca	gac	gat	gtc	tcc	aaa	atc	aat	gaa	gga	att	580
	Leu	Asn	Thr	Arg	Leu	Thr	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Gly	Ile	
			175					180					185				
25	ggc	gac	aaa	att	gga	atg	ttc	ttt	caa	tca	ata	gca	aca	ttt	ttc	acc	628
	Gly	Asp	Lys	Ile	Gly	Met	Phe	Phe	Gln	Ser	Ile	Ala	Thr	Phe	Phe	Thr	
		190					195					200					
30	ggt	ttt	ata	gtg	ggg	ttt	aca	cgt	ggt	tgg	aag	cta	acc	ctt	gtg	att	676
	Gly	Phe	Ile	Val	Gly	Phe	Thr	Arg	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile	
	205				210						215					220	
35	ttg	gcc	atc	agc	cct	gtt	ctt	gga	ctt	tca	gcc	gcc	atc	tgg	gca	aag	724
	Leu	Ala	Ile	Ser	Pro	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys	
					225					230					235		
40	ata	cta	tct	tca	ttt	act	gat	aaa	gaa	ctc	ttg	gcc	tat	gca	aaa	gct	772
	Ile	Leu	Ser	Ser	Phe	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	
				240					245					250			
45	gga	gca	gta	gct	gaa	gaa	gtc	tta	gca	gca	atc	aga	act	gtg	att	gcc	820
	Gly	Ala	Val	Ala	Glu	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	
			255					260					265				
50	ttt	gga	gga	caa	aag	aaa	gaa	ctt	gaa	agg	tac	aac	aaa	aat	tta	gaa	868
	Phe	Gly	Gly	Gln	Lys	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	
		270					275					280					
55	gaa	gct	aaa	gga	att	ggg	ata	aag	aaa	gct	atc	acg	gcc	aac	att	tct	916
	Glu	Ala	Lys	Gly	Ile	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	
	285					290					295					300	
60	att	ggt	gcc	gct	ttc	tta	ttg	atc	tat	gca	tca	tat	gct	ctg	gct	ttc	964
	Ile	Gly	Ala	Ala	Phe	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	
					305					310					315		
65	tgg	tat	ggg	acc	tcc	ttg	gtc	ctc	tcc	agt	gaa	tat	tct	att	gga	caa	1012
	Trp	Tyr	Gly	Thr	Ser	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Ser	Ile	Gly	Gln	
				320					325					330			
70	gta	ctc	act	gtc	ttc	ttt	tct	gta	tta	att	ggg	gct	ttt	agt	att	gga	1060
	Val	Leu	Thr	Val	Phe	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly	
			335					340					345				
75	cag	gca	tcc	cca	agc	att	gaa	gca	ttt	gca	aac	gca	aga	gga	gca	gct	1108
	Gln	Ala	Ser	Pro	Ser	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	

		350					355					360						
5		tat	gaa	atc	ttc	aag	ata	att	gac	aat	aaa	cca	agc	att	gac	agc	tat	1156
		Tyr	Glu	Ile	Phe	Lys	Ile	Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	
		365					370					375					380	
10		tcg	aag	agt	gga	cat	aaa	cca	gat	aat	att	aag	gga	aat	ttg	gaa	ttc	1204
		Ser	Lys	Ser	Gly	His	Lys	Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	
						385					390					395		
15		aaa	aat	gtt	cac	ttc	agt	tac	cct	tct	cga	aaa	gaa	gtt	aag	atc	tta	1252
		Lys	Asn	Val	His	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	
					400					405					410			
20		aag	ggt	ctc	aac	ctg	aag	gtt	cag	agt	ggg	cag	aca	gtg	gcg	ctg	gtt	1300
		Lys	Gly	Leu	Asn	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	
				415					420					425				
25		ggg	aac	agt	ggc	tgc	ggg	aag	agc	acg	acc	gtg	cag	ctg	atg	cag	agg	1348
		Gly	Asn	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	
			430					435					440					
30		ctc	tat	gac	ccc	aca	gat	ggc	atg	gtc	tgt	att	gat	gga	cag	gac	att	1396
		Leu	Tyr	Asp	Pro	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	
		445					450					455					460	
35		agg	acc	ata	aat	gta	agg	cat	ctt	cgg	gaa	att	act	ggt	gtg	gtg	agt	1444
		Arg	Thr	Ile	Asn	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	
						465					470					475		
40		cag	gag	cct	gtg	ttg	ttt	gcc	acc	acg	ata	gct	gaa	aac	att	cgc	tat	1492
		Gln	Glu	Pro	Val	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	
					480					485					490			
45		ggc	cgc	gaa	aat	gtc	acc	atg	gat	gag	att	gag	aaa	gct	gtt	aag	gaa	1540
		Gly	Arg	Glu	Asn	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	
				495					500					505				
50		gcc	aat	gcc	tat	gat	ttt	atc	atg	aaa	cta	cct	aat	aaa	ttt	gac	act	1588
		Ala	Asn	Ala	Tyr	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	
			510					515					520					
55		ctg	gtt	gga	gag	aga	ggg	gcc	cag	ctg	agt	ggt	gga	cag	aaa	cag	aga	1636
		Leu	Val	Gly	Glu	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	
		525					530					535					540	
60		atc	gcc	att	gct	cgg	gcc	ctg	gtt	cgc	aac	ccc	aag	att	ctt	ctg	ctg	1684
		Ile	Ala	Ile	Ala	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	
						545					550					555		
65		gat	gag	gca	acg	tca	gct	ctg	gac	act	gaa	agt	gaa	gca	gtg	gtt	cag	1732
		Asp	Glu	Ala	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	
					560					565					570			
70		gtg	gcc	ctg	gat	aag	gcc	aga	aaa	ggc	cgg	act	acc	att	gtg	ata	gct	1780
		Val	Ala	Leu	Asp	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	
				575				580						585				
75		cat	cgt	ttg	tct	aca	gtt	cgt	aat	gcc	gat	gtc	att	gct	ggt	ttt	gat	1828
		His	Arg	Leu	Ser	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	

	590	595	600	
5	gat gga gtc att gtg gag Asp Gly Val Ile Val Glu 605 610	aaa gga aat cat Lys Gly Asn His 615	gat gaa ctc atg aaa gag Asp Glu Leu Met Lys Glu 615 620	1876
10	aag ggc att tac ttc Lys Gly Ile Tyr Phe 625	aaa ctt gtc aca atg Lys Leu Val Thr Met 630	cag aca aga gga aat gaa Gln Thr Arg Gly Asn Glu 635	1924
15	att gag tta gaa aat gcc Ile Glu Leu Glu Asn Ala 640	act ggt gaa tcc aaa Thr Gly Glu Ser Lys 645	agt gaa agt gat gcc Ser Glu Ser Asp Ala 650	1972
20	ttg gaa atg tct cca Leu Glu Met Ser Pro 655	aaa gat tca ggg tcc Lys Asp Ser Gly Ser 660	agt tta ata aaa aga Ser Leu Ile Lys Arg Arg 665	2020
25	tca act cgc agg agt Ser Thr Arg Arg Ser 670	ata cat gca cca caa Ile His Ala Pro Gln 675	ggc caa gac aga aag ctt Gln Asp Arg Lys Leu 680	2068
30	ggt aca aaa gag gac Gly Thr Lys Glu Asp 685	ttg aat gag aat gta Leu Asn Glu Asn Val 690	cct cca gtt tcc ttc tgg Pro Pro Val Ser Phe Trp 695 700	2116
35	agg att ctg aag ctg Arg Ile Leu Lys Leu 705	aac tca act gaa tgg Asn Ser Thr Glu Trp 710	cct tat ttt gtg gtt ggt Pro Tyr Phe Val Val Gly 715	2164
40	ata ttt tgt gct att Ile Phe Cys Ala Ile 720	ata aac gga ggc ctg Ile Asn Gly Gly Leu 725	caa cca gca ttt tca ata Gln Pro Ala Phe Ser Ile 730	2212
45	ata ttt tca agg att Ile Phe Ser Arg Ile 735	ata ggg atc ttt acc Ile Gly Ile Phe Thr 740	cga gat gag gat cct gaa Arg Asp Glu Asp Pro Glu 745	2260
50	aca aaa cga cag aat Thr Lys Arg Gln Asn 750	agt aac atg ttt tct Ser Asn Met Phe Ser 755	gta ttg ttt cta gtc ctt Val Leu Phe Leu Val Leu 760	2308
55	gga att att tct ttt Gly Ile Ile Ser Phe 765	att aca ttt ttc ctc Ile Thr Phe Phe Leu 770 775	cag ggc ttc aca ttt ggc Gln Gly Phe Thr Phe Gly 775 780	2356
60	aaa gct ggg gag atc Lys Ala Gly Glu Ile 785	ctc act aag cgg ctt Leu Thr Lys Arg Leu 790	cga tac atg gtt ttc aga Arg Tyr Met Val Phe Arg 795	2404
65	tcc atg ctg aga cag Ser Met Leu Arg Gln 800	gat gtc agc tgg ttt Asp Val Ser Trp Phe 805	gat gac cct aaa aac acc Asp Asp Pro Lys Asn Thr 810	2452
70	act gga gca ttg aca Thr Gly Ala Leu Thr 815	acc agg ctt gcc aat Thr Arg Leu Ala Asn 820	gat gcg gct caa gtt aaa Asp Ala Ala Gln Val Lys 825	2500
75	ggg gct ata ggt tcc Gly Ala Ile Gly Ser 835	agg ctt gct gtc att Arg Leu Ala Val Ile 840	acc cag aat ata gca aat Thr Gln Asn Ile Ala Asn 845	2548

	830	835	840	
5	ctt ggg aca ggc att att ata tcc tta atc tat ggt tgg caa tta aca Leu Gly Thr Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr 845 850 855 860			2596
10	ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt Leu Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val 865 870 875			2644
15	gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu 880 885 890			2692
20	gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr 895 900 905			2740
25	gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca cag Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln 910 915 920			2788
30	agt ttg caa gta cca tac aga aac tct ttg agg aaa gca cac atc ttc Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe 925 930 935 940			2836
35	ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gct Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala 945 950 955			2884
40	ggc tgt ttc cgg ttt ggt gcc tac ttg gtg gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn 960 965 970			2932
45	ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met 975 980 985			2980
50	gca gtg ggg cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys 990 995 1000			3028
55	gta tca gca gcc cac gtc atc atg atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile 1005 1010 1015 1020			3076
60	gac agc tac agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn 1025 1030 1035			3124
65	gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile 1040 1045 1050			3172
70	ccc gtg ctc cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu 1055 1060 1065			3220
75	gcc ctc gta ggt agc agt ggc tgt ggg aag agc aca gtt gtt cag ctc Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu 1070 1075 1080			3268

1070

1075

1080

	cta gag cgc ttc tat	gac ccc ttg gct ggt	tca gtg cta att gat ggc	3316
	Leu Glu Arg Phe Tyr	Asp Pro Leu Ala Gly	Ser Val Leu Ile Asp Gly	
5	1085	1090	1095 1100	
	aaa gag ata aag cac	ctg aat gtc cag tgg	ctc cga gca cac ctg ggc	3364
	Lys Glu Ile Lys His	Leu Asn Val Gln Trp	Leu Arg Ala His Leu Gly	
		1105 1110	1115	
10				
	atc gtg tct cag gag	ccc atc ctg ttt gac	tgc agc att gcc gag aac	3412
	Ile Val Ser Gln Glu	Pro Ile Leu Phe Asp	Cys Ser Ile Ala Glu Asn	
		1120 1125	1130	
15				
	att gcc tat gga gac	aac agc cgg gtc gta	tca cat gaa gag att atg	3460
	Ile Ala Tyr Gly Asp	Asn Ser Arg Val Val	Ser His Glu Glu Ile Met	
		1135 1140	1145	
20				
	cag gca gcc aag gag	gcc aac ata cac cac	ttc atc gag aca ctc cct	3508
	Gln Ala Ala Lys Glu	Ala Asn Ile His His	Phe Ile Glu Thr Leu Pro	
		1150 1155	1160	
25				
	gag aaa tac aac acc	aga gta gga gac aaa	gga acc cag ctc tct ggt	3556
	Glu Lys Tyr Asn Thr	Arg Val Gly Asp Lys	Gly Thr Gln Leu Ser Gly	
		1165 1170	1175 1180	
30				
	ggc cag aaa cag cgc	att gcc ata gct cgc	gct ctt gtt aga cag cct	3604
	Gly Gln Lys Gln Arg	Ile Ala Ile Ala Arg	Ala Leu Val Arg Gln Pro	
		1185 1190	1195	
35				
	cat att ttg ctt ttg	gat gaa gct aca tca	gct ctg gat aca gaa agt	3652
	His Ile Leu Leu Leu	Asp Glu Ala Thr Ser	Ala Leu Asp Thr Glu Ser	
		1200 1205	1210	
40				
	gaa aag gtt gtc caa	gaa gcc ctg gac aaa	gcc aga gaa ggc cgc acc	3700
	Glu Lys Val Val Gln	Glu Ala Leu Asp Lys	Ala Arg Glu Gly Arg Thr	
		1215 1220	1225	
45				
	tgc att gtg atc gcc	cac cgc ttg tcc acc	atc cag aat gca gat tta	3748
	Cys Ile Val Ile Ala	His Arg Leu Ser Thr	Ile Gln Asn Ala Asp Leu	
		1230 1235	1240	
50				
	ata gtg gtg ttt cag	aat ggc aaa gtc aag	gag cat ggc aca cat caa	3796
	Ile Val Val Phe Gln	Asn Gly Lys Val Lys	Glu His Gly Thr His Gln	
		1245 1250	1255 1260	
55				
	cag ctg ctg gcc cag	aaa ggc atc tat ttt	tcc atg gtc agt gtc cag	3844
	Gln Leu Leu Ala Gln	Lys Gly Ile Tyr Phe	Ser Met Val Ser Val Gln	
		1265 1270	1275	
60				
	gct gga gca aag cgc	tagtgaactg tggccatatg	agctgttaaa tatttttttaa	3899
	Ala Gly Ala Lys Arg			
		1280		
55				
	tatttgtgtt aaaacatggc	atttaaatcaa agttaaaagg	tgagcactta ctggaaaaac	3959
	tatgtagaac tacctgttta	acatttcttg ctgcaactga	agatcattcc accaagttca	4019
	gagcttcag attttataat	taaaggaacc aaaagaaaca	ttatctgatg gaataaaata	4079
	ctggtgttaa ttgcattata	aaattataga gtaattcaaa	gtagattttg ttaataaatt	4139
	gtataatttt tgtttatatt	ttatttgtaa cttactgctt	tgctgaaaga ttatagaagt	4199
	ggtaaaaagt actgaatgtt	tgaataaagt gctagctata	ataaaaactaa acttttatat	4259

5

10

15

20

25

30

35

40

45

50

55

60

Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly
 420 425 430
 Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro
 435 440 445
 5 Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile Arg Thr Ile Asn
 450 455 460
 Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser Gln Glu Pro Val
 465 470 475 480
 10 Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn
 485 490 495
 Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr
 500 505 510
 Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr Leu Val Gly Glu
 515 520 525
 15 Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala
 530 535 540
 Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr
 545 550 555 560
 20 Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp
 565 570 575
 Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser
 580 585 590
 Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile
 595 600 605
 25 Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr
 610 615 620
 Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu Ile Glu Leu Glu
 625 630 635 640
 30 Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met Ser
 645 650 655
 Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg Arg
 660 665 670
 Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys Glu
 675 680 685
 35 Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu Lys
 690 695 700
 Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys Ala
 705 710 715 720
 40 Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser Arg
 725 730 735
 Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg Gln
 740 745 750
 Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile Ser
 755 760 765
 45 Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu
 770 775 780
 Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg
 785 790 795 800
 50 Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu
 805 810 815
 Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly
 820 825 830
 Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly
 835 840 845
 55 Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu Leu
 850 855 860
 Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met
 865 870 875 880
 60 Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly
 885 890 895

Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu
 900 905 910
 Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val
 915 920 925
 5 Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe
 930 935 940
 Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg
 945 950 955 960
 10 Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val
 965 970 975
 Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln
 980 985 990
 Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala
 995 1000 1005
 15 His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser
 1010 1015 1020
 Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn
 1025 1030 1035 1040
 20 Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln
 1045 1050 1055
 Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly
 1060 1065 1070
 Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe
 1075 1080 1085
 25 Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys
 1090 1095 1100
 His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln
 1105 1110 1115 1120
 30 Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly
 1125 1130 1135
 Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys
 1140 1145 1150
 Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn
 1155 1160 1165
 35 Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln
 1170 1175 1180
 Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu
 1185 1190 1195 1200
 40 Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val
 1205 1210 1215
 Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile
 1220 1225 1230
 Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe
 1235 1240 1245
 45 Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala
 1250 1255 1260
 Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys
 1265 1270 1275 1280
 Arg

50

<210> 24

<211> 4279

<212> DNA

55

<213> Canis familiaris

<220>

<221> CDS

<222> (17)...(3859)

60

<400> 24
ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag 52
Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu
1 5 10

5 aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa gag aag aaa 100
Lys Asn Phe Trp Lys Met Gly Lys Lys Ser Lys Lys Lys Glu Lys Lys
15 20 25

10 gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat 148
Glu Lys Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn
30 35 40

15 tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc 196
Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile
45 50 55 60

20 cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca 244
His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr
65 70 75

25 gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt 292
Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val
80 85 90

30 ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat 340
Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His
95 100 105

35 ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt 388
Leu Glu Glu Glu Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly
110 115 120

40 gct ggc gtg ctg gtg gct gct tac atc cag gtt tca ttc tgg tgc ctg 436
Ala Gly Val Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu
125 130 135 140

45 gca gca gga aga cag ata ctc aaa att aga aaa caa ttt ttt cat gct 484
Ala Ala Gly Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala
145 150 155

50 atc atg cga cag gag att ggc tgg ttt gac gtg cat gac gtt ggg gag 532
Ile Met Arg Gln Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu
160 165 170

55 ctt aac acc cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att 580
Leu Asn Thr Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile
175 180 185

60 ggc gac aaa att gga atg ttc ttt caa tca ata gca aca ttt ttc acc 628
Gly Asp Lys Ile Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr
190 195 200

65 ggt ttt ata gtg ggg ttt aca cgt ggt tgg aag cta acc ctt gtg att 676
Gly Phe Ile Val Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile
205 210 215 220

70 ttg gcc atc agc cct gtt ctt gga ctt tca gcc gcc atc tgg gca aag 724
Leu Ala Ile Ser Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys
225 230 235

	ata cta tct tca ttt act gat aaa gaa ctc ttg gcc tat gca aaa gct	772
	Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala	
	240 245 250	
5	gga gca gta gct gaa gaa gtc tta gca gca atc aga act gtg att gcc	820
	Gly Ala Val Ala Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala	
	255 260 265	
10	ttt gga gga caa aag aaa gaa ctt gaa agg tac aac aaa aat tta gaa	868
	Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu	
	270 275 280	
15	gaa gct aaa gga att ggg ata aag aaa gct atc acg gcc aac att tct	916
	Glu Ala Lys Gly Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser	
	285 290 295 300	
20	att ggt gcc gct ttc tta ttg atc tat gca tca tat gct ctg gct ttc	964
	Ile Gly Ala Ala Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe	
	305 310 315	
25	tgg tat ggg acc tcc ttg gtc ctc tcc agt gaa tat tct att gga caa	1012
	Trp Tyr Gly Thr Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln	
	320 325 330	
30	gta ctc act gtc ttc ttt tct gta tta att ggg gct ttt agt att gga	1060
	Val Leu Thr Val Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly	
	335 340 345	
35	cag gca tcc cca agc att gaa gca ttt gca aac gca aga gga gca gct	1108
	Gln Ala Ser Pro Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala	
	350 355 360	
40	tat gaa atc ttc aag ata att gac aat aaa cca agc att gac agc tat	1156
	Tyr Glu Ile Phe Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr	
	365 370 375 380	
45	tcg aag agt gga cat aaa cca gat aat att aag gga aat ttg gaa ttc	1204
	Ser Lys Ser Gly His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe	
	385 390 395	
50	aaa aat gtt cac ttc agt tac cct tct cga aaa gaa gtt aag atc tta	1252
	Lys Asn Val His Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu	
	400 405 410	
55	aag ggt ctc aac ctg aag gtt cag agt ggg cag aca gtg gcg ctg gtt	1300
	Lys Gly Leu Asn Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val	
	415 420 425	
60	ggg aac agt ggc tgc ggg aag agc acg acc gtg cag ctg atg cag agg	1348
	Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg	
	430 435 440	
65	ctc tat gac ccc aca gat ggc atg gtc tgt att gat gga cag gac att	1396
	Leu Tyr Asp Pro Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile	
	445 450 455 460	
70	agg acc ata aat gta agg cat ctt cgg gaa att act ggt gtg gtg agt	1444
	Arg Thr Ile Asn Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser	
	465 470 475	

	cag gag cct gtg ttg ttt gcc acc acg ata gct gaa aac att cgc tat	1492
	Gln Glu Pro Val Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr	
	480 485 490	
5	ggc cgc gaa aat gtc acc atg gat gag att gag aaa gct gtt aag gaa	1540
	Gly Arg Glu Asn Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu	
	495 500 505	
10	gcc aat gcc tat gat ttt atc atg aaa cta cct aat aaa ttt gac act	1588
	Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr	
	510 515 520	
15	ctg gtt gga gag aga ggg gcc cag ctg agt ggt gga cag aaa cag aga	1636
	Leu Val Gly Glu Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg	
	525 530 535 540	
20	atc gcc att gct cgg gcc ctg gtt cgc aac ccc aag att ctt ctg ctg	1684
	Ile Ala Ile Ala Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Leu	
	545 550 555	
25	gat gag gca acg tca gct ctg gac act gaa agt gaa gca gtg gtt cag	1732
	Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln	
	560 565 570	
30	gtg gcc ctg gat aag gcc aga aaa ggc cgg act acc att gtg ata gct	1780
	Val Ala Leu Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala	
	575 580 585	
35	cat cgt ttg tct aca gtt cgt aat gcc gat gtc att gct ggt ttt gat	1828
	His Arg Leu Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp	
	590 595 600	
40	gat gga gtc att gtg gag aaa gga aat cat gat gaa ctc atg aaa gag	1876
	Asp Gly Val Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu	
	605 610 615 620	
45	aag ggc att tac ttc aaa ctt gtc aca atg cag aca aga gga aat gaa	1924
	Lys Gly Ile Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu	
	625 630 635	
50	att gag tta gaa aat gcc act ggt gaa tcc aaa agt gaa agt gat gcc	1972
	Ile Glu Leu Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala	
	640 645 650	
55	ttg gaa atg tct cca aaa gat tca ggg tcc agt tta ata aaa aga aga	2020
	Leu Glu Met Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg	
	655 660 665	
60	tca act cgc agg agt ata cat gca cca caa ggc caa gac aga aag ctt	2068
	Ser Thr Arg Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu	
	670 675 680	
65	ggt aca aaa gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg	2116
	Gly Thr Lys Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp	
	685 690 695 700	
70	agg att ctg aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt	2164
	Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly	
	705 710 715	

	ata ttt tgt gct att ata aac gga ggc ctg caa cca gca ttt tca ata	2212
	Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile	
	720 725 730	
5	ata ttt tca agg att ata ggg atc ttt acc cga gat gag gat cct gaa	2260
	Ile Phe Ser Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu	
	735 740 745	
10	aca aaa cga cag aat agt aac atg ttt tct gta ttg ttt cta gtc ctt	2308
	Thr Lys Arg Gln Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu	
	750 755 760	
15	gga att att tct ttt att aca ttt ttc ctc cag ggc ttc aca ttt ggc	2356
	Gly Ile Ile Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly	
	765 770 775 780	
20	aaa gct ggg gag atc ctc act aag cgg ctt cga tac atg gtt ttc aga	2404
	Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg	
	785 790 795	
25	tcc atg ctg aga cag gat gtc agc tgg ttt gat gac cct aaa aac acc	2452
	Ser Met Leu Arg Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr	
	800 805 810	
30	act gga gca ttg aca acc agg ctt gcc aat gat gcg gct caa gtt aaa	2500
	Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys	
	815 820 825	
35	ggg gct ata ggt tcc agg ctt gct gtc att acc cag aat ata gca aat	2548
	Gly Ala Ile Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn	
	830 835 840	
40	ctt ggg aca ggc att att ata tcc tta atc tat ggt tgg caa tta aca	2596
	Leu Gly Thr Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr	
	845 850 855 860	
45	ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt	2644
	Leu Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val	
	865 870 875	
50	gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta	2692
	Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu	
	880 885 890	
55	gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act	2740
	Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr	
	895 900 905	
60	gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca cag	2788
	Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln	
	910 915 920	
65	agt ttg caa gta cca tac aga aac tct ttg agg aaa gca cac atc ttc	2836
	Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe	
	925 930 935 940	
70	ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gct	2884
	Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala	
	945 950 955	

	ggc	tgt	ttc	cgg	ttt	ggg	gcc	tac	ttg	gtg	gca	aat	gag	ttc	atg	aac	2932
	Gly	Cys	Phe	Arg	Phe	Gly	Ala	Tyr	Leu	Val	Ala	Asn	Glu	Phe	Met	Asn	
				960					965					970			
5																	
	ttt	cag	gat	gtt	ctt	ttg	gta	ttc	tca	gct	att	gtc	ttt	ggg	gcc	atg	2980
	Phe	Gln	Asp	Val	Leu	Leu	Val	Phe	Ser	Ala	Ile	Val	Phe	Gly	Ala	Met	
			975					980					985				
10																	
	gca	gtg	ggg	cag	gtc	agt	tca	ttt	gct	cct	gac	tat	gcc	aaa	gcc	aaa	3028
	Ala	Val	Gly	Gln	Val	Ser	Ser	Phe	Ala	Pro	Asp	Tyr	Ala	Lys	Ala	Lys	
			990				995					1000					
15																	
	gta	tca	gca	gcc	cac	gtc	atc	atg	atc	att	gaa	aaa	agc	cct	ctg	att	3076
	Val	Ser	Ala	Ala	His	Val	Ile	Met	Ile	Ile	Glu	Lys	Ser	Pro	Leu	Ile	
	1005					1010					1015					1020	
20																	
	gac	agc	tac	agc	cct	cac	ggc	ctc	aag	cca	aat	acg	ttg	gaa	gga	aat	3124
	Asp	Ser	Tyr	Ser	Pro	His	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Glu	Gly	Asn	
				1025					1030						1035		
25																	
	gtg	aca	ttt	aat	gag	gtc	gtg	ttc	aac	tat	ccc	act	cga	cca	gac	atc	3172
	Val	Thr	Phe	Asn	Glu	Val	Val	Phe	Asn	Tyr	Pro	Thr	Arg	Pro	Asp	Ile	
			1040					1045					1050				
30																	
	ccc	gtg	ctc	cag	ggg	ctg	agc	ctc	gag	gtg	aag	aag	ggc	cag	acg	ctg	3220
	Pro	Val	Leu	Gln	Gly	Leu	Ser	Leu	Glu	Val	Lys	Lys	Gly	Gln	Thr	Leu	
			1055				1060						1065				
35																	
	gcc	ctc	gta	ggg	agc	agt	ggc	tgt	ggg	aag	agc	aca	ggt	ggt	cag	ctc	3268
	Ala	Leu	Val	Gly	Ser	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Val	Val	Gln	Leu	
		1070					1075					1080					
40																	
	cta	gag	cgc	ttc	tat	gac	ccc	ttg	gct	ggg	tca	gtg	cta	att	gat	ggc	3316
	Leu	Glu	Arg	Phe	Tyr	Asp	Pro	Leu	Ala	Gly	Ser	Val	Leu	Ile	Asp	Gly	
	1085					1090					1095					1100	
45																	
	aaa	gag	ata	aag	cac	ctg	aat	gtc	cag	tgg	ctc	cga	gca	cac	ctg	ggc	3364
	Lys	Glu	Ile	Lys	His	Leu	Asn	Val	Gln	Trp	Leu	Arg	Ala	His	Leu	Gly	
				1105					1110						1115		
50																	
	atc	gtg	tct	cag	gag	ccc	at										

cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt 3652
 His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser
 1200 1205 1210

5

gaa aag gtt gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc 3700
 Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr
 1215 1220 1225

10

tgc att gtg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta 3748
 Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu
 1230 1235 1240

15

ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa 3796
 Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln
 1245 1250 1255 1260

20

cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag 3844
 Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln
 1265 1270 1275

25

gct gga gca aag cgc tagtgaactg tggccatatg agctgttaaa tatttttttaa 3899
 Ala Gly Ala Lys Arg
 1280

30

tatttgtgtt aaaacatggc atttaaatcaa agttaaaggg tgagcactta ctggaaaaac 3959
 tatgtagaac tacctgttta acatttcttg ctgcaactga agatcattcc accaagttca 4019
 gagtcttcag attttataat taaaggaacc aaaagaaaca ttatctgatg gaataaaata 4079
 ctggtgttaa ttgcattata aaattataga gtaattcaaa gtagattttg ttaataaatt 4139
 gtataatttt tgtttatatt ttatttgttaa cttactgctt tgctgaaaga ttatagaagt 4199
 ggtaaaaagt actgaatggt tgaataaagt gctagctata ataaaactaa acttttatat 4259
 caaaaaaaaa aaaaaaaaaa

35

<210> 25
 <211> 1281
 <212> PRT
 <213> Canis familiaris

40

<400> 25
 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp
 1 5 10 15
 Lys Met Gly Lys Lys Ser Lys Lys Lys Glu Lys Lys Glu Lys Lys Pro
 20 25 30

45

Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg
 35 40 45
 Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala
 50 55 60
 Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala
 65 70 75 80

50

Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu
 85 90 95
 Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu
 100 105 110

55

Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu
 115 120 125
 Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg
 130 135 140

60

Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln
 145 150 155 160
 Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg

					165					170					175				
	Leu	Thr	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Gly	Ile	Gly	Asp	Lys	Ile			
				180					185					190					
5	Gly	Met	Phe	Phe	Gln	Ser	Ile	Ala	Thr	Phe	Phe	Thr	Gly	Phe	Ile	Val			
			195					200					205						
	Gly	Phe	Thr	Arg	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile	Leu	Ala	Ile	Ser			
		210					215					220							
	Pro	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys	Ile	Leu	Ser	Ser			
	225					230					235					240			
10	Phe	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	Gly	Ala	Val	Ala			
				245						250					255				
	Glu	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	Phe	Gly	Gly	Gln			
			260						265					270					
15	Lys	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	Glu	Ala	Lys	Gly			
			275					280					285						
	Ile	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	Ile	Gly	Ala	Ala			
		290					295					300							
	Phe	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	Trp	Tyr	Gly	Thr			
	305					310					315					320			
20	Ser	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Ser	Ile	Gly	Gln	Val	Leu	Thr	Val			
				325							330					335			
	Phe	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly	Gln	Ala	Ser	Pro			
				340						345					350				
25	Ser	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	Tyr	Glu	Ile	Phe			
			355				360						365						
	Lys	Ile	Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	Ser	Lys	Ser	Gly			
		370					375					380							
	His	Lys	Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	Lys	Asn	Val	His			
					390						395					400			
30	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	Asn			
				405						410					415				
	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly			
			420						425					430					
35	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro			
			435					440					445						
	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn			
		450					455					460							
	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	Val			
		465				470					475					480			
40	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn			
				485						490					495				
	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr			
			500						505					510					
45	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu			
			515					520					525						
	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala			
		530					535					540							
	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr			
		545				550					555					560			
50	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp			
				565						570					575				
	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser			
				580					585					590					
55	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile			
			595				600						605						
	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr			
		610					615					620							
	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	Glu			
		625				630					635					640			
60	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	Ser			

					645					650					655	
	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	Arg
				660					665					670		
5	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	Glu
			675					680					685			
	Asp	Leu	Asn	Glu	Asn	Val	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Leu	Lys
		690					695					700				
	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	Ala
	705					710					715				720	
10	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	Arg
					725					730					735	
	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	Gln
				740					745					750		
15	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	Ser
			755					760					765			
	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu
	770						775					780				
	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg
	785					790					795				800	
20	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu
					805					810					815	
	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly
				820				825						830		
25	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly
			835					840					845			
	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu
	850						855					860				
	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	Met
	865					870					875				880	
30	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	Gly
					885					890					895	
	Lys	Ile	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	Leu
				900				905						910		
35	Thr	Arg	Glu	Gln	Lys	Phe	Glu	Tyr	Met	Tyr	Ala	Gln	Ser	Leu	Gln	Val
			915					920						925		
	Pro	Tyr	Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	Gly	Val	Ser	Phe
		930					935					940				
	Ser	Ile	Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	Gly	Cys	Phe	Arg
	945					950					955				960	
40	Phe	Gly	Ala	Tyr	Leu	Val	Ala	Asn	Glu	Phe	Met	Asn	Phe	Gln	Asp	Val
					965				970						975	
	Leu	Leu	Val	Phe	Ser	Ala	Ile	Val	Phe	Gly	Ala	Met	Ala	Val	Gly	Gln
				980				985						990		
45	Val	Ser	Ser	Phe	Ala	Pro	Asp	Tyr	Ala	Lys	Ala	Lys	Val	Ser	Ala	Ala
			995					1000						1005		
	His	Val	Ile	Met	Ile	Ile	Glu	Lys	Ser	Pro	Leu	Ile	Asp	Ser	Tyr	Ser
		1010					1015						1020			
	Pro	His	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Glu	Gly	Asn	Val	Thr	Phe	Asn
	1025					1030					1035				1040	
50	Glu	Val	Val	Phe	Asn	Tyr	Pro	Thr	Arg	Pro	Asp	Ile	Pro	Val	Leu	Gln
					1045					1050					1055	
	Gly	Leu	Ser	Leu	Glu	Val	Lys	Lys	Gly	Gln	Thr	Leu	Ala	Leu	Val	Gly
					1060				1065						1070	
55	Ser	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Val	Val	Gln	Leu	Leu	Glu	Arg	Phe
			1075					1080						1085		
	Tyr	Asp	Pro	Leu	Ala	Gly	Ser	Val	Leu	Ile	Asp	Gly	Lys	Glu	Ile	Lys
		1090					1095					1100				
	His	Leu	Asn	Val	Gln	Trp	Leu	Arg	Ala	His	Leu	Gly	Ile	Val	Ser	Gln
	1105					1110					1115				1120	
60	Glu	Pro	Ile	Leu	Phe	Asp	Cys	Ser	Ile	Ala	Glu	Asn	Ile	Ala	Tyr	Gly

1125 1130 1135
 Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys
 1140 1145 1150
 5 Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn
 1155 1160 1165
 Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln
 1170 1175 1180
 Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu
 1185 1190 1195 1200
 10 Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val
 1205 1210 1215
 Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile
 1220 1225 1230
 Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe
 1235 1240 1245
 15 Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala
 1250 1255 1260
 Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys
 1265 1270 1275 1280
 20 Arg

25 <210> 26
 <211> 4279
 <212> DNA
 <213> Canis familiaris

30 <220>
 <221> CDS
 <222> (17)...(3859)

<400> 26
 ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag 52
 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu
 35 1 5 10
 aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa gag aag aaa 100
 Lys Asn Phe Trp Lys Met Gly Lys Lys Ser Lys Lys Lys Glu Lys Lys
 15 20 25
 40 gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat 148
 Glu Lys Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn
 30 35 40
 45 tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc 196
 Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile
 45 50 55 60
 50 cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca 244
 His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr
 65 70 75
 gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt 292
 Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val
 55 80 85 90
 ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat 340
 Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His
 95 100 105
 60

	ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt Leu Glu Glu Glu Met Thr Thr Tyr Ala Tyr Tyr Ser Gly Ile Gly 110 115 120	388
5	gct ggc gtg ctg gtg gct gct tac atc cag gtt tca ttc tgg tgc ctg Ala Gly Val Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu 125 130 135 140	436
10	gca gca gga aga cag ata ctc aaa att aga aaa caa ttt ttt cat gct Ala Ala Gly Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala 145 150 155	484
15	atc atg cga cag gag att ggc tgg ttt gac gtg cat gac gtt ggg gag Ile Met Arg Gln Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu 160 165 170	532
20	ctt aac acc cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att Leu Asn Thr Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile 175 180 185	580
25	ggc gac aaa att gga atg ttc ttt caa tca ata gca aca ttt ttc acc Gly Asp Lys Ile Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr 190 195 200	628
30	ggt ttt ata gtg ggg ttt aca cgt ggt tgg aag cta acc ctt gtg att Gly Phe Ile Val Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile 205 210 215 220	676
35	ttg gcc atc agc cct gtt ctt gga ctt tca gcc gcc atc tgg gca aag Leu Ala Ile Ser Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys 225 230 235	724
40	ata cta tct tca ttt act gat aaa gaa ctc ttg gcc tat gca aaa gct Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala 240 245 250	772
45	gga gca gta gct gaa gaa gtc tta gca gca atc aga act gtg att gcc Gly Ala Val Ala Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala 255 260 265	820
50	ttt gga gga caa aag aaa gaa ctt gaa agg tac aac aaa aat tta gaa Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu 270 275 280	868
55	gaa gct aaa gga att ggg ata aag aaa gct atc acg gcc aac att tct Glu Ala Lys Gly Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser 285 290 295 300	916
60	att ggt gcc gct ttc tta ttg atc tat gca tca tat gct ctg gct ttc Ile Gly Ala Ala Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe 305 310 315	964
65	tgg tat ggg acc tcc ttg gtc ctc tcc agt gaa tat act att gga caa Trp Tyr Gly Thr Ser Leu Val Leu Ser Ser Glu Tyr Thr Ile Gly Gln 320 325 330	1012
70	gta ctc act gtc ttc ttt tct gta tta att ggg gct ttt agt att gga Val Leu Thr Val Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly 335 340 345	1060

	cag gca tcc cca agc att gaa gca ttt gca aac gca aga gga gca gct Gln Ala Ser Pro Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala 350 355 360	1108
5	tat gaa atc ttc aag ata att gac aat aaa cca agc att gac agc tat Tyr Glu Ile Phe Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr 365 370 375 380	1156
10	tcg aag agt gga cat aaa cca gat aat att aag gga aat ttg gaa ttc Ser Lys Ser Gly His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe 385 390 395	1204
15	aaa aat gtt cac ttc agt tac cct tct cga aaa gaa gtt aag atc tta Lys Asn Val His Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu 400 405 410	1252
20	aag ggt ctc aac ctg aag gtt cag agt ggg cag aca gtg gcg ctg gtt Lys Gly Leu Asn Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val 415 420 425	1300
25	ggg aac agt ggc tgc ggg aag agc acg acc gtg cag ctg atg cag agg Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg 430 435 440	1348
30	ctc tat gac ccc aca gat ggc atg gtc tgt att gat gga cag gac att Leu Tyr Asp Pro Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile 445 450 455 460	1396
35	agg acc ata aat gta agg cat ctt cgg gaa att act ggt gtg gtg agt Arg Thr Ile Asn Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser 465 470 475	1444
40	cag gag cct gtg ttg ttt gcc acc acg ata gct gaa aac att cgc tat Gln Glu Pro Val Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr 480 485 490	1492
45	ggc cgc gaa aat gtc acc atg gat gag att gag aaa gct gtt aag gaa Gly Arg Glu Asn Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu 495 500 505	1540
50	gcc aat gcc tat gat ttt atc atg aaa cta cct aat aaa ttt gac act Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr 510 515 520	1588
55	ctg gtt gga gag aga ggg gcc cag ctg agt ggt gga cag aaa cag aga Leu Val Gly Glu Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg 525 530 535 540	1636
60	atc gcc att gct cgg gcc ctg gtt cgc aac ccc aag att ctt ctg ctg Ile Ala Ile Ala Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Leu 545 550 555	1684
	gat gag gca acg tca gct ctg gac act gaa agt gaa gca gtg gtt cag Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln 560 565 570	1732
	gtg gcc ctg gat aag gcc aga aaa ggc cgg act acc att gtg ata gct Val Ala Leu Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala 575 580 585	1780

	cat	cgt	ttg	tct	aca	gtt	cgt	aat	gcc	gat	gtc	att	gct	ggg	ttt	gat	1828
	His	Arg	Leu	Ser	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	
	590						595					600					
5	gat	gga	gtc	att	gtg	gag	aaa	gga	aat	cat	gat	gaa	ctc	atg	aaa	gag	1876
	Asp	Gly	Val	Ile	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	
	605					610					615					620	
10	aag	ggc	att	tac	ttc	aaa	ctt	gtc	aca	atg	cag	aca	aga	gga	aat	gaa	1924
	Lys	Gly	Ile	Tyr	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	
					625					630					635		
15	att	gag	tta	gaa	aat	gcc	act	ggg	gaa	tcc	aaa	agt	gaa	agt	gat	gcc	1972
	Ile	Glu	Leu	Glu	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	
				640					645					650			
20	ttg	gaa	atg	tct	cca	aaa	gat	tca	ggg	tcc	agt	tta	ata	aaa	aga	aga	2020
	Leu	Glu	Met	Ser	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	
			655					660					665				
25	tca	act	cgc	agg	agt	ata	cat	gca	cca	caa	ggc	caa	gac	aga	aag	ctt	2068
	Ser	Thr	Arg	Arg	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	
			670				675					680					
30	ggg	aca	aaa	gag	gac	ttg	aat	gag	aat	gta	cct	cca	gtt	tcc	ttc	tgg	2116
	Gly	Thr	Lys	Glu	Asp	Leu	Asn	Glu	Asn	Val	Pro	Pro	Val	Ser	Phe	Trp	
	685					690					695					700	
35	agg	att	ctg	aag	ctg	aac	tca	act	gaa	tgg	cct	tat	ttt	gtg	gtt	ggg	2164
	Arg	Ile	Leu	Lys	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	
					705					710					715		
40	ata	ttt	tgt	gct	att	ata	aac	gga	ggc	ctg	caa	cca	gca	ttt	tca	ata	2212
	Ile	Phe	Cys	Ala	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	
				720					725					730			
45	ata	ttt	tca	agg	att	ata	ggg	atc	ttt	acc	cga	gat	gag	gat	cct	gaa	2260
	Ile	Phe	Ser	Arg	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	
			735				740						745				
50	aca	aaa	cga	cag	aat	agt	aac	atg	ttt	tct	gta	ttg	ttt	cta	gtc	ctt	2308
	Thr	Lys	Arg	Gln	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	
		750					755					760					
55	gga	att	att	tct	ttt	att	aca	ttt	ttc	ctc	cag	ggc	ttc	aca	ttt	ggc	2356
	Gly	Ile	Ile	Ser	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	
	765					770					775					780	
60	aaa	gct	ggg	gag	atc	ctc	act	aag	cgg	ctt	cga	tac	atg	gtt	ttc	aga	2404
	Lys	Ala	Gly	Glu	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	
					785					790					795		
65	tcc	atg	ctg	aga	cag	gat	gtc	agc	tgg	ttt	gat	gac	cct	aaa	aac	acc	2452
	Ser	Met	Leu	Arg	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	
				800					805					810			
70	act	gga	gca	ttg	aca	acc	agg	ctt	gcc	aat	gat	gcg	gct	caa	gtt	aaa	2500
	Thr	Gly	Ala	Leu	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	
			815					820					825				

	ggg gct ata ggt tcc agg ctt gct gtc att acc cag aat ata gca aat Gly Ala Ile Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn 830 835 840	2548
5	ctt ggg aca ggc att att ata tcc tta atc tat ggt tgg caa tta aca Leu Gly Thr Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr 845 850 855 860	2596
10	ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt Leu Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val 865 870 875	2644
15	gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu 880 885 890	2692
20	gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr 895 900 905	2740
25	gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca cag Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln 910 915 920	2788
30	agt ttg caa gta cca tac aga aac tct ttg agg aaa gca cac atc ttc Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe 925 930 935 940	2836
35	ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gct Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala 945 950 955	2884
40	ggc tgt ttc cgg ttt ggt gcc tac ttg gtg gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn 960 965 970	2932
45	ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met 975 980 985	2980
50	gca gtg ggg cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys 990 995 1000	3028
55	gta tca gca gcc cac gtc atc atg atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile 1005 1010 1015 1020	3076
60	gac agc tac agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn 1025 1030 1035	3124
65	gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile 1040 1045 1050	3172
70	ccc gtg ctc cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu 1055 1060 1065	3220

	gcc ctc gta ggt agc agt ggc tgt ggg aag agc aca gtt gtt cag ctc Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu 1070 1075 1080	3268
5	cta gag cgc ttc tat gac ccc ttg gct ggt tca gtg cta att gat ggc Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly 1085 1090 1095 1100	3316
10	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly 1105 1110 1115	3364
15	atc gtg tct cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn 1120 1125 1130	3412
20	att gcc tat gga gac aac agc cgg gtc gta tca cat gaa gag att gtg Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Ile Val 1135 1140 1145	3460
	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro 1150 1155 1160	3508
25	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly 1165 1170 1175 1180	3556
30	ggc cag aaa cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro 1185 1190 1195	3604
35	cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser 1200 1205 1210	3652
40	gaa aag gtt gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr 1215 1220 1225	3700
	tgc att gtg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu 1230 1235 1240	3748
45	ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln 1245 1250 1255 1260	3796
50	cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln 1265 1270 1275	3844
55	gct gga gca aag cgc tagtgaactg tggccatatg agctgttaaa tatttttttaa Ala Gly Ala Lys Arg 1280	3899
60	tatttggtgtt aaaacatggc atttaatacaa agttaaagg tgagcactta ctggaaaaac tatgtagaac tacctgttta acattttcttg ctgcaactga agatcattcc accaagttca gagtccttcag attttataat taaaggaacc aaaagaaaca ttatctgatg gaataaaata ctgggtgttaa ttgcattata aaattataga gtaattcaaa gtagattttg ttaataaaatt	3959 4019 4079 4139

gtataatttt tgtttatatt ttatttgtaa cttactgctt tgctgaaaga ttatagaagt 4199
 ggtaaaaaagt actgaatggt tgaataaagt gctagctata ataaaactaa acttttatat 4259
 caaaaaaaaaa aaaaaaaaaa

5 <210> 27
 <211> 1281
 <212> PRT
 <213> Canis familiaris

10 <400> 27
 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp
 1 5 10 15
 Lys Met Gly Lys Lys Ser Lys Lys Lys Glu Lys Lys Glu Lys Lys Pro
 20 25 30
 15 Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg
 35 40 45
 Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala
 50 55 60
 Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala
 65 70 75 80
 20 Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu
 85 90 95
 Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu
 100 105 110
 25 Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu
 115 120 125
 Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg
 130 135 140
 Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln
 145 150 155 160
 30 Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg
 165 170 175
 Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile
 180 185 190
 35 Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val
 195 200 205
 Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser
 210 215 220
 Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser
 225 230 235 240
 40 Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala
 245 250 255
 Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln
 260 265 270
 45 Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Gly
 275 280 285
 Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala
 290 295 300
 Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr
 305 310 315 320
 50 Ser Leu Val Leu Ser Ser Glu Tyr Thr Ile Gly Gln Val Leu Thr Val
 325 330 335
 Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro
 340 345 350
 55 Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe
 355 360 365
 Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly
 370 375 380
 His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His
 385 390 395 400

	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	Asn
				405						410					415	
	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly
				420					425					430		
5	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro
			435					440					445			
	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn
		450					455					460				
10	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	Val
	465					470					475					480
	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn
				485						490					495	
	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr
			500						505					510		
15	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu
		515						520					525			
	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala
		530					535					540				
20	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr
	545					550					555					560
	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp
				565						570					575	
	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser
			580						585					590		
25	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile
		595						600					605			
	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr
		610					615					620				
30	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	Glu
	625					630					635					640
	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	Ser
				645						650					655	
	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	Arg
			660						665					670		
35	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	Glu
			675					680					685			
	Asp	Leu	Asn	Glu	Asn	Val	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Leu	Lys
		690					695					700				
40	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	Ala
	705					710					715					720
	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	Arg
				725						730					735	
	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	Gln
			740						745					750		
45	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	Ser
			755					760					765			
	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu
		770					775					780				
50	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg
	785					790					795					800
	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu
				805						810					815	
	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly
			820					825						830		
55	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly
			835					840					845			
	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu
		850					855					860				
60	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	Met
	865					870					875					880

Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly
 885 890 895
 Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu
 900 905 910
 5 Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val
 915 920 925
 Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe
 930 935 940
 10 Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg
 945 950 955 960
 Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val
 965 970 975
 Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln
 980 985 990
 15 Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala
 995 1000 1005
 His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser
 1010 1015 1020
 20 Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn
 1025 1030 1035 1040
 Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln
 1045 1050 1055
 Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly
 1060 1065 1070
 25 Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe
 1075 1080 1085
 Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys
 1090 1095 1100
 30 His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln
 1105 1110 1115 1120
 Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly
 1125 1130 1135
 Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Val Gln Ala Ala Lys
 1140 1145 1150
 35 Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn
 1155 1160 1165
 Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln
 1170 1175 1180
 40 Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu
 1185 1190 1195 1200
 Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val
 1205 1210 1215
 Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile
 1220 1225 1230
 45 Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe
 1235 1240 1245
 Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala
 1250 1255 1260
 50 Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys
 1265 1270 1275 1280
 Arg

55 <210> 28
 <211> 52
 <212> DNA
 <213> Artificial Sequence

60 <220>
 <223> Synthetic oligonucleotide

<400> 28
nntttttttt tttttttttt tttttttttt ttcgccggcg acttaagatc tt 52

5 <210> 29
<211> 27
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Synthetic oligonucleotide

<400> 29
ccatcctaatac gactcact gtagggc 27

15 <210> 30
<211> 34
<212> DNA
<213> Canis familiaris

20 <400> 30
gcaaatagctt caatgcttgg ggatgcctgt ccaa 34

25 <210> 31
<211> 33
<212> DNA
<213> Canis familiaris

30 <400> 31
gagctggggtt cctttgtctc ctactctggt gtt 33

35 <210> 32
<211> 23
<212> DNA
<213> Canis familiaris

<400> 32
gcaaatagctg gttgcaggcc tcc 23